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Very  large  biomedical  research  databases,  containing  electronic  health  records  
(EHR)  and  genomic  data  from  millions  of  patients,  have  been  heralded  recently  for  
their  potential  to  accelerate  scientific  discovery  and  produce  dramatic  improvements  
in   medical   treatments.   Research   enabled   by   these   databases   may   also   lead   to  
profound   changes   in   law,   regulation,   social   policy,   and   even   litigation   strategies.  
<HWLV³ELJGDWD´QHFHVVDULO\EHWWHUGDWD"  
  This  paper  makes  an  original  contribution  to  the  legal  literature  by  focusing  on  
what   can   go   wrong   in   the   process   of   biomedical   database   research   and   what  
precautions  are  necessary  to  avoid  critical  mistakes.  We  address  three  main  reasons  
for   approaching   such   research   with   care   and   being   cautious   in   relying   on   its  
outcomes   for   purposes   of   public   policy   or   litigation.   First,   the   data   contained   in  
biomedical   databases   is   surprisingly   likely   to   be   incorrect   or   incomplete.   Second,  
systematic  biases,  arising  from  both  the  nature  of  the  data  and  the  preconceptions  of  
investigators,   are   serious   threats   to   the   validity   of   research   results,   especially   in  
answering   causal   questions.   Third,   data  mining   of   biomedical   databases   makes   it  
easier   for   individuals   with   political,   social,   or   economic   agendas   to   generate  
ostensibly   scientific   but   misleading   research   findings   for   the   purpose   of  
manipulating  public  opinion  and  swaying  policymakers.  
In  short,   this  paper  sheds  much-­needed  light  on  the  problems  of  credulous  and  
uninformed  acceptance   of   research   results   derived   from  biomedical   databases.   An  
understanding  of  the  pitfalls  of  big  data  analysis  is  of  critical  importance  to  anyone  
who  will   rely  on  or  dispute   its  outcomes,   including   lawyers,   policymakers,  and   the  
public   at   large.   The   Article   also   recommends   technical,   methodological,   and  
educational  interventions  to  combat  the  dangers  of  database  errors  and  abuses .  
I.  INTRODUCTION  
In   2009,   the   Journal   of   Psychiatric   Research   published   an   article   that   linked  
abortion  to  psychiatric  disorders.1  7KHUHVHDUFKHUVH[DPLQHG³QDWLRQDOGDWDVHWVZLWK
UHSURGXFWLYH KLVWRU\ DQGPHQWDO KHDOWK YDULDEOHV´ WR IRUPXODWH WKHLU ILQGLQJV 2  The  
study   was   widely   cited   among   abortion   opponents,3   and   several   states   enacted  
legislation  requiring  that  women  seeking  abortions  receive  counseling  that  includes  
warnings  about  potential   long-­term  mental  health  problems.4   In  2012,  however,   the  
study  was  discredited  by  scientists  who  scrutinized  its  design  and  found  that  it  was  
severely   flawed.5   The   original   researchers   neglected   to   compare   women   with  
                                                                                                  
1  Priscilla  K.  Coleman  et  al.,  Induced  Abortion  and  Anxiety,  Mood,  and  Substance  Abuse  
Disorders:  Isolating  the  Effects  of  Abortion  in  the  National  Comorbidity  Survey ,  43  J.  PSYCHIATRIC  
RES.  770,  773  (2009),  available  at  http://www.journalofpsychiatricresearch.com/article/S0022-­
3956(08)00238-­0/abstract.    
2  Id.  at  770.  
3  Sharon  Begley,  Journal  Disavows  Study  Touted  by  U.S.  Abortion  Foes,  REUTERS  (Mar.  7,  




to  inform  women  of  this  danger).    
4  Counseling  and  Waiting  Periods  for  Abortion ,  STATE  POLICIES  IN  BRIEF  (Guttmacher  Inst.,  
New  York,  N.Y.),  May  1,  2012,  at  1,  3,  available  at  
http://www.guttmacher.org/statecenter/spibs/spib_MWPA.pdf.     
5  Ronald  C.  Kessler  &  Alan  F.  Schatzberg,  Reply  to  Letter  to  the  Editor,  Commentary  on  
Abortion  Studies  of  Steinberg  and  Finer  (Social  Science  &  Medicine  2011;;  72:72±82)  and  Coleman  




unplanned   pregnancies   who   did   have   abortions   to   those  who   did   not   and   failed   to  
focus  only  on  mental  health  problems  that  manifested  after  terminated  pregnancies.6  
Thus,  what  appeared  to  be  solid  scientific  evidence  turned  out  not  to  be  so,  but  not  
before  having  significant  impact  on  some  state  legislatures.  
The  accelerating  transition  from  paper  medical  files  to  electronic  health  records  
(EHR)  systems7  is  facilitating  the  creation  of  large  health  information  databases.8  In  
the   future,   these  may   include   significant   genetic   information   because  many   EHRs  
will   contain   or   be   linked   to  genetic   data   about  patients.9   In   addition,   scientists   are  
constructing   large   databases   from   genome   sequencing   projects.10   Biomedical  
databases   can   serve   as   invaluable   resources   for   researchers.   There   is   justified  
enthusiasm  about  the  potential  for  research  using  them  to  yield  improved  treatments  
and   beneficial   policy   changes,   and   we   have   elaborated   on   the   promise   of   such  
research   in  prior  work.11  Computer  processing  of  digitized  records  permits   fast  and  
relatively   inexpensive   data   analysis   and   synthesis,   which   can   enable   scientific  
discoveries  and  ultimately  affect  public  policy  and  law.12  Notably,  the  size  and  scope  
of   integrated   biomedical   databases   may   allow   researchers   to   overcome   certain  
problems   they  encounter  with   smaller-­scale   studies,   such  as  unrepresentative   study  
groups  and  insufficient  statistical  power  or  precision.13  
EHR-­based   research   is   likely   to   become   increasingly   important   because   of  
several   federally   sponsored   initiatives.   These   include   comparative   effectiveness  
research   that   is   promoted   by   the   Patient   Protection   and   Affordable   Care   Act   of  
201014   and   post-­marketing   surveillance   authorized   by   the   Food   and   Drug  
Administration  Amendments  Act  of  2007.15  
Anyone   considering   the   outcomes   of   record-­based   studies,   however,   must  
recognize   the   shortcomings   of   contemporary   EHR   and   genomic   data   and   the  
                                                                                                                                                                                                                                            
(Journal  of  Psychiatric  Research  2009;;43:770±6  &  Journal  of  Psychiatric  Research  2011;;45:1133±
4),  46  J.  PSYCHIATRIC  RES.  410,  410-­11  (2012).  
6  Id.  at  410.  
7  David  Blumenthal  &  Marilyn  Tavenner,  7KH³0HDQLQJIXO8VH´5HJXODWLRQIRU(OHFWURQLF
Health  Records,  363  NEW  ENG.  J.  MED.  501,  501  (2010).  Others  may  call  EHRs  electronic  medical  
UHFRUGV(05)RUWKHVDNHRIVLPSOLFLW\ZHXVH³(+5´FRQVLVWHQWO\WKURXJKRXWDQGGRQRWEHOLHYH
there  is  a  substantive  distinction  between  the  two  terms.  See  Peter  Garrett  &Joshua  J.  Seidman,  EMR  





8  Sharona  Hoffman  &  Andy  Podgurski,  Balancing  Privacy,  Autonomy,  and  Scientific  Needs  in  
Electronic  Health  Records  Research,  65  SMU  L.  REV.  85,  91-­94  (2012).  
9  M.A.  Hoffman,  The  Genome-­Enabled  Electronic  Medical  Record,  40  J.  BIOMEDICAL  
INFORMATICS  44,  44  (2006);;  Isaac  S.  Kohane,  Using  Electronic  Health  Records  to  Drive  Discovery  in  
Disease  Genomics,  12  NATURE  REV.  GENETICS  417,  417  (2011).    
10  ARTHUR  M.  LESK,  INTRODUCTION  TO  GENOMICS  104-­05  (2d  ed.  2012).    
11  Hoffman  &  Podgurski,  supra  note  8,  at  97-­102.  
12  See  Abel  N.  Kho  et  al.,  Electronic  Medical  Records  for  Genetic  Research:  Results  of  the  
eMERGE  Consortium,  3  SCI.  TRANSL.  MED.  78re1,  5  (2011);;  Charles  Safran,  Toward  a  National  
Framework  for  the  Secondary  Use  of  Health  Data:  An  American  Medical  Informatics  Association  
White  Paper,  14  J.  AM.  MED.  INFORMATICS  ASS¶N  1,  2  (2007);;  Mark  G.  Weiner  &  Peter  J.  Embi,  
Toward  Reuse  of  Clinical  Data  for  Research  and  Quality  Improvement:  The  End  of  the  Beginning? ,  
151  ANN.  INTERN.  MED.  359,  359-­60  (2009).  
13  See  infra  notes  225-­226.    
14  42  U.S.C.  §  1320e  (Supp  IV.  2010);;  see  infra  notes  97-­100.    
15  Food  and  Drug  Administration  Amendments  Act  of  2007,  Pub.  L.  No.  110-­85,  121  Stat.  823  
(codified  as  amended  in  scattered  sections  of  21  U.S.C.);;  see  infra  Part  II.B.3.  
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challenges  of  inferring  causal  effects  correctly.16  Much  has  been  written  about  EHR  
privacy  risks,  but  this  paper  makes  a  different  contribution  to  the  legal  literature  by  
focusing  on  what  can  go  wrong  in  the  process  of  biomedical  data  analysis  and  what  
precautions  must  be  taken  to  avoid  critical  mistakes.  It  sheds  much-­needed  light  on  
the   problems   of   naïve   or   irresponsible   use   of   biomedical   databases,   and   these  
problems  are  likely  to  become  much  more  common  and  pressing  in  the  near  future.  
The  data-­use  pitfalls  we  discuss  are  familiar  to  competent  biomedical  researchers  but  
must  be  understood  by  lawyers,  bioethicists,  policymakers,  and  anyone  else  who  will  
rely  on  research  results.  
We   XVH WKH WHUP ³ELRPHGLFDO GDWDEDVHV´ WR PHDQ GDWDEDVHV RI (+5s   and/or  
genomic  information  as  well  as  decentralized,  federated  database  systems.17  Thus,  in  
this  paper,  we  address  non-­interventional  research,  that  is,  research  that  is  based  on  
UHYLHZ RI UHFRUGV ZKLFK ZH DOVR FDOO ³UHFRUGV-­EDVHG UHVHDUFK´ RU ³REVHUYDWLRQDO
UHVHDUFK´18  We  do  not  intend  to  comment  on  clinical  studies  in  which  investigators  
conduct   experiments   using   human   subjects19   or   on   research   involving   the  
administration  of  questionnaires  or  surveys.    
Observational  studies  are  relevant  to  the  law  because  their  outcomes  can  lead  to  
regulatory   enforcement   actions   or   to   legislative   changes,   and   they   can   be   used   as  
evidence   in   litigation.   For   example,   observational   studies  may   reveal   that   use   of   a  
medication   or   device   causes   patients   to   suffer   serious   adverse   events,   and   this  
discovery   may   induce   the   Food   and   Drug   Administration   (FDA)   to   intervene.20  
Observational  studies  may  also  uncover  statistical  associations  between  illnesses  and  
exposure  to  certain  substances  or  between  diseases  and  genetic  variations.21  Reports  
of   these   associations  may   be   used   in   litigation   by   both  plaintiffs   and   defendants. 22  
Plaintiffs  may  file  tort  cases  against  product  manufacturers,  and  toxic  tort  defendants  
                                                                                                  
16  Pamela  N.  Peterson  &  Paul  D.  Varosy,  Observational  Comparative  Effectiveness  Research:  
Comparative  Effectiveness  and  Caveat  Emptor,  5  CIRCULATION  CARDIOVASC.  QUALITY  &  OUTCOMES  
150,  151  (2012)  (ZDUQLQJWKDW³DSULPDU\GHWHUPLQDQWRIWKHTXDOLW\RIDQ\VWXG\LVWKHTXDOLW\RIWKH   
GDWD´DQGWKDW³KRZWKHUHVXOWVRIREVHUYDWLRQDOVWXGLHVDUHLQWHUSUHWHGDQGXVHG´LVRIFULWLFDO
importance).  
17  See  infra  note  37  and  accompanying  text  for  definition  of  federated  database  system.  In  other  
contexts,  biomedical  databases  can  also  consist  of  data  collected  from  large-­scale  clinical  studies.  
Prakash  M.  Nadkarni,  Managing  Attribute²Value  Clinical  Trials  Data  Using  the  ACT/DB  Client²
Server  Database  System,  5  J.  AM.  MED.  INFORMATICS  ASS¶N  139,  139  (1998)  (VWDWLQJWKDW³FRPSOH[
trials  need  sophisticated  database  expertise  not  readily  available  to  individual  investigators´    
18  CHARLES  P.  FRIEDMAN  &  JEREMY  C.  WYATT,  EVALUATION  METHODS  IN  BIOMEDICAL  
INFORMATICS  369  (Kathryn  Hannah  &  Marion  Ball  eds.,  2d  ed.  2006)  (defining  observational  studies  
as  LQYROYLQJDQ³>D@SSURDFKWRVWXG\GHVLJQWKDWHQWDLOVQRH[SHULPHQWDOPDQLSXODWLRQ´BRYAN  F.  J.  
MANLY,  THE  DESIGN  AND  ANALYSIS  OF  RESEARCH  STUDIES  1  (1992)  (explaining  that  observational  
VWXGLHVLQYROYHWKHFROOHFWLRQRIGDWD³E\REVHUYLQJVRPHSURFHVVZhich  may  not  be  well-­
XQGHUVWRRG´  PAUL  R.  ROSENBAUM,  OBSERVATIONAL  STUDIES  vii  (2d  ed.  2001)  (stating  that  an  
REVHUYDWLRQDOVWXG\LV³DQHPSLULFLQYHVWLJDWLRQRIWUHDWPHQWVSROLFLHVRUH[SRVXUHVDQGWKHHIIHFWV
they  cause,  but  it  differs  from  an  experiment  in  that  the  investigator  cannot  control  the  assignment  of  
WUHDWPHQWVWRVXEMHFWV´:KHQXVLQJWKHWHUP³REVHUYDWLRQDOVWXGLHV´ZHUHIHURQO\WRVWXGLHV
involving  the  review  of  existing  records  or  data.  
19  MANLY,  supra  note  18,  at  1  (explaining  WKDWH[SHULPHQWDOFOLQLFDOVWXGLHVLQYROYH³WKH
collection  of  data  on  a  process  when  there  is  some  manipulation  of  variables  that  are  assumed  to  affect  
WKHRXWFRPHRIDSURFHVVNHHSLQJRWKHUYDULDEOHVFRQVWDQWDVIDUDVSRVVLEOH´+RIIPDQ	3RGJXUVNL
supra  note  8,  at  98-­102  (contrasting  clinical  trials  and  observational  studies).  
20  See  infra  notes  115-­119  and  accompanying  text.  
21  DAVID  L.  FAIGMAN  ET  AL.,  MODERN  SCIENTIFIC  EVIDENCE:  STANDARDS,  STATISTICS,  AND  
RESEARCH  METHODS  338-­42  (student  ed.  2008).    
22  Id.  




PD\ LQ WXUQ XVH VFLHQWLILF HYLGHQFH WR DWWDFN SODLQWLIIV¶ FODLPV DQG DUJXH that  
VRPHWKLQJRWKHUWKDQWKHLUSURGXFWVFDXVHGWKHSODLQWLIIV¶LOOQHVVHV 23    
News   outlets   frequently   report   new   research   findings.   Press   reports   often  
trumpet   the   discovery   that   factor   A   LV VWDWLVWLFDOO\ DVVRFLDWHG ZLWK RU ³OLQNHG´ WR
condition   B.   The   availability   of   large   biomedical   databases   greatly   facilitates   the  
discovery  of  such  associations.  However,  the  nature  of  such  data  can  complicate  the  
determination  of  whether  factor  A  actually  causes  or  contributes  to  condition  B.  We  
address   three   main   reasons   for   a   cautious   approach   to   incorporating   record-­based  
research  into  the  law.    
First,   the   data   contained   in   biomedical   databases   may   be   of   poor   quality,  
incomplete,  or  even  deliberately  distorted.24  For  example,  a  recent  New  York  Times  
article  reported  that  the  automated  features  of  EHR  systems  make  it  easy  for  doctors  
to   exaggerate   the   care   they   provided   for   purposes   of   Medicare   reimbursement.25  
Doctors   can   simply   click   on   menu   items   or   copy   and   paste   narrative   in   order   to  
justify   billing,   and   some   lack   scruples   with   respect   to   overstating   or   even  
fictionalizing   what   occurred   during   clinical   encounters.26   Such   practices   not   only  
defraud  Medicare,  but  also  compromise   the  accuracy  of  EHRs.  Moreover,   they  can  
systematically  bias  research  results.  
Second,   valid   causal   analysis   is   much   more   difficult   with   observational   data  
than   with   data   from   well-­designed   and   well-­executed   randomized   experiments   or  
clinical   trials.27  Unfortunately,   having   ODUJH DPRXQWV RI GDWD ³ELJ GDWD´   does   not  
necessarily   ameliorate   this   problem.   The   challenges   of   properly   analyzing  
observational   data   and   making   appropriate   causal   inferences28   are   illustrated   in   a  
SDSHU HQWLWOHG ³'RHV 2EHVLW\ 6KRUWHQ /LIH" 7KH ,PSRUWDQFH RI :HOO-­Defined  
,QWHUYHQWLRQV WR $QVZHU &DXVDO 4XHVWLRQV´29   The   researchers   critique   previous  
observational   studies   of   obesity   and  mortality   and   conclude   that   they  were   flawed  
because   they   failed   to   specify   what   interventions   were   used   to   reduce   body   mass  
index  (BMI).  Different  methods  of  changing  BMI  (e.g.,   surgery,  diet,  exercise)  are  
associated   with   different   risk   levels   for   patients,   and   mortality   may   actually   be  
associated   with   the   treatment   rather   than   the   underlying   obesity   in   some   cases.30  
Thus,   researchers   cannot   reach   meaningful   conclusions   about   the   benefits   of  
reducing  BMI  without  knowing  what  interventions  were  used  to  achieve  this  goal  in  
each  instance.31    
7KLUG LQGLYLGXDOV ZLWK SROLWLFDO VRFLDO RU HFRQRPLF DJHQGDV PD\ ³PLQH´ RU
³GUHGJH´ ELRPHGLFDO GDWDEDVHV WR ILQG OLQNV VWDWLVWLFDO DVVRFLDWLRQV EHWZHHQ
                                                                                                  
23  Id.  at  339-­40  (explaining  that  epidemiological  evidence  has  already  played  an  important  role  in  
many  mass  tort  cases);;  Steve  C.  Gold,  The  More  We  Know,  the  Less  Intelligent  We  Are?±How  
Genomic  Information  Should,  and  Should  Not,  Change  Toxic  Tort  Causation  Doctrine,  34  HARV.  
ENVTL.  L.  REV.  369,  412-­17  (2010)  (GLVFXVVLQJJHQHVDQGRWKHUWR[LQVDVDOWHUQDWHFDXVHVRISODLQWLIIV¶
injuries).  
24  See  infra  Part  III.  
25  Reed  Abelson  et  al.,  Medicare  Bills  Rise  as  Records  Turn  Electronic ,  N.Y.  TIMES,  Sept.  21,  
2012,  at  A1,  A3,  http://www.nytimes.com/2012/09/22/business/medicare-­billing-­rises-­at-­hospitals-­
with-­electronic-­records.html?_r=0.  
26  Id.  
27  See  infra  Part  IV.  
28  Samantha  Kleinberg  &  George  Hripcsak,  A  Review  of  Causal  Inference  for  Biomedical  
Informatics,  44  J.  BIOMED.  INFORMATICS  1102,  1102  (2011)  (GHILQLQJFDXVDOLQIHUHQFHDV³WKHSURFHVV
RIXQFRYHULQJFDXVDOUHODWLRQVKLSVIURPGDWD´  
29  See  Miguel  A.  Hernán  &  Sarah  L.  Taubman,  Does  Obesity  Shorten  Life?  The  Importance  of  
Well-­Defined  Interventions  to  Answer  Causal  Questions,  32  INT¶L  J.  OBESITY  S8  (2008).  
30  Id.  at  S13.  
31  Id.  
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actions,  behaviors,  or  policies,  on  the  one  hand,  and  outcomes  of  public  interest,  on  
the  other  hand,   for   the  purpose  of  manipulating  public  opinion  and  swaying  policy  
decisions.32  The  risk  of  misinterpretation  of  such  results  by  interested  parties  is  high  
if  they  are  not  well-­trained  and  scrupulous  researchers.  Research  about  the  purported  
link  between  abortion  and  psychiatric  disorders,  discussed  above,  demonstrates  this  
potential  danger.33  Pro-­life  advocates  used  questionable  scientific  data  to  promote  a  
controversial  legislative  agenda.    
The   paper   proceeds   as   follows.   Part   II   provides   background   information.   It  
describes  ongoing  efforts   to  build  biomedical  databases  and  analyzes   the   relevance  
of   observational   studies   to   law   and   public   policy.   Part   III   analyzes   common  
shortcomings   of   biomedical   data   that   should   give   analysts   and   the   public   pause.  
These   include   input   errors,   incomplete   or   fragmented   records,   and   flaws   in   data  
coding  or  standardization.  
Part   IV   provides   an   in-­depth   discussion   of   causal   inference   and   of   biases  
affecting   observational   studies.   It   analyzes   the   challenges   of   inferring   causation   in  
observational   studies,   including   the   problems   of   selection   bias,   confounding   bias,  
and   measurement   bias.   Indeed,   confounding   bias   and   selection   bias   will   likely   be  
fundamental  concepts  in  legal  reasoning  in  big  data  environments.  Part  V  addresses  
the   potential   use   of   observational   study   outcomes   for   purposes   of   furthering  
political,  social,  and  economic  agendas.    
Finally,   Part   VI   analyzes   the   factors   that   contribute   to   sound   research   and  
provides   guidance   for   policymakers   and   litigants   seeking   to   determine   whether  
particular  research  outcomes  are  reliable.  The  quality  of  digitized  research  databases  
and  the  studies  that  grow  out  of  them  will  depend  not  only  on  good   technology,  but  
also   on   persistent   human   efforts   to   safeguard   the   integrity   of   research   projects.  
Technological   advances   are  needed   to   enhance   interoperability,   data   capture,   data-­
extraction  capabilities,  and  system  usability.  In  addition,  clinicians  and  patients  can  
partner  to  assess  the  validity  of  the  data  contained  in  EHRs,  and  investigators  must  
be  scrupulous  about  study  design,  analysis,  and  publication.  This  Part  also  describes  
and   critiques   the   use   of   causal   inference   diagrams,   which   have   received   l ittle  
attention  in  the  legal  literature  but  is  increasingly  common  in  other  fields.34  
Equally  important  is  ensuring  that  the  legal  community,  journal  editors,  and  the  
public  at  large  are  not  misled  by  those  who  appear  to  engage  in  scientific  endeavors  
but  who  in  truth  misuse  evidence  to  promote  their  own  political,  social,  or  economic  
agendas.  Legal  practitioners  must  understand  the  complex  issues  raised  by  big  data  
in   order   to   play   a   useful   role   in   protecting   the   public¶V   interests.   To   this   end,   we  
recommend  the  development  of  law  school  and  other  educational  programs  about  the  
challenges  of  observational  data  analysis  and  causal  inference.    
II.  BACKGROUND  
Researchers   and   other   analysts   may   gain   access   to   large-­scale   collections   of  
biomedical  data  in  two  primary  ways.  First,  health  information  can  be  collected  into  
                                                                                                  
32  See  infra  Part  V.  
33  See  supra  notes  1-­6  and  accompanying  text.  
34  See  Nancy  C.  Staudt  &  Tyler  J.  VanderWeele,  Methodological  Advances  and  Empirical  Legal  
Scholarship:  A  1RWHRQ&R[DQG0LOHV¶V9RWLQJ5LJKWV$FW6WXG\   109  COLUM.  L.  REV.  SIDEBAR  42,  43  
(2009)  (DVVHUWLQJWKDWE\WKHPHWKRGRORJ\RIFDXVDOGLDJUDPVKDG³EHFRPHSRSXODULQDQXPEHU
of  disciplines  ±  including  statistics,  biostatistics,  epidemiology,  and  computer  science  .  .  .  [but  had  
\HW@WRDSSHDULQWKHHPSLULFDOODZOLWHUDWXUH´  




large  databases  and  de-­identified   to  protect  patient  privacy.35  Such  databases  could  
be   limited   to   particular   hospital   systems,   be   expanded   to   cover   entire   regions,   or  
even   be   national   in   scope.36   IQ WKH DOWHUQDWLYH UHVHDUFKHUV PD\ XVH D ³IHGHUDWHG
V\VWHP´ E\ ZKLFK PHGLFDO LQVWLWXWLRQV PDQDJH DQG PDLQWDLQ FRQWURO RI WKHLU RZQ
databases,  but  they  allow  researchers  to  submit  statistical  queries  through  a  standard  
web   service   in  order   to  obtain   summary   statistics   for   a   study  population.37  Trusted  
third-­party  aggregators  can  operate  the  query  service.38    
Many   large   biomedical   databases   and   federated   systems   already   exist   and   are  
used  for  non-­treatment  purposes.39  7KHWHUP³VHFRQGDU\XVH´UHIHUVWRWKHXWLOLzation  
of  health   information  outside   the  clinical   setting.40  This  Part  describes  a   sample  of  
data-­collection   initiatives.   It  also  discusses  how   experts   in   the  biomedical   research,  
quality  assessment,  public  health,  and  litigation  arenas  may  utilize  EHR  data.    
  A.  ONGOING  INITIATIVES  TO  CREATE  BIOMEDICAL  DATABASES  
The   Federal   Government   has   clearly   recognized   the   usefulness   of   biomedical  
databases   and   enthusiastically   supports   database   projects.   The   Obama  
Administration  has  announced  an  overarching  effort  calOHG WKH³%LJ'DWD5HVHDUFK
DQG'HYHORSPHQW,QLWLDWLYH´³Big  Data´).41  7KHLQLWLDWLYH¶VSXUSRVHVDUHWRDGYDQFH
cutting-­HGJHWHFKQRORJLHVQHHGHGWRJDWKHUDQGSURFHVV³KXJHTXDQWLWLHVRIGDWD ;;´to  
employ   those   technologies   to   promote   scientific   discovery,   improved   national  
security,  and  education;;  and  to  expand  the  workforce  skilled  in  these  technologies.42  
Big  Data  will  involve  six  federal  agencies  and  departments  and  is  estimated  to  cost  
$200   million.43   As   part   of   Big   Data,   the   National   Institutes   of   Health   (NIH)   will  
make   data   from   its   1000   Genomes   Project   publicly   available   through   cloud  
computing.44  
                                                                                                  
35  Hoffman  &  Podgurski,  supra  note  8,  at  128-­30.  
36  WILSON  D.  PACE  ET  AL.,  AGENCY  FOR  HEALTH  CARE  RES.  &  QUALITY,  DISTRIBUTED  
AMBULATORY  RESEARCH  IN  THERAPEUTIC  NETWORK  (DARTNET):  SUMMARY  REPORT  ii  (2009),  
available  at  http://www.effectivehealthcare.ahrq.gov/ehc/products/53/151/2009_0728DEcIDE_  
DARTNet.pdf.  
37  Griffin  M.  Weber  et  al.,  The  Shared  Health  Research  Information  Network  (SHRINE):  A  
Prototype  Federated  Query  Tool  for  Clinical  Data  Repositories,  16  J.  AM.  MED.  INFORMATICS  ASS¶N  
624,  624  (2009).  $IHGHUDWHGQHWZRUNFDQEHGHILQHGDVRQHWKDW³OLQNVJHRJUDSKLFDOO\DQG
organizationally  separate  databases  to  allow  a  single  query  to  pull  information  from  multiple  
databases  while  PDLQWDLQLQJWKHSULYDF\DQGFRQILGHQWLDOLW\RIHDFKGDWDEDVH´PACE,  supra  note  36,  at  
ii.    
38  Hoffman  &  Podgurski,  supra  note  8,  at  131-­33.  
39  Id.  at  91.    
40  Jessica  S.  Ancker  et  al.,  Root  Causes  Underlying  Challenges  to  Secondary  Use  of  Data ,  AMIA  
ANNUAL  SYMPOSIUM  PROCEEDINGS  57,  57  (2011);;  Taxiarchis  Botsis  et  al.,  Secondary  Use  of  EHR:  
Data  Quality  Issues  and  Informatics  Opportunities,  AMIA  JOINT  SUMMITS  ON  TRANSL.  SCI.  1,  1  
(2010).    
41  Press  Release,  Office  of  Sci.  &  Tech.  Policy,  Exec.  Office  of  the  President,  Obama  
$GPLQLVWUDWLRQ8QYHLOV³%LJ'DWD´,QLWLDWLYH$QQRXQFHV0LOOLRQLQ1HZ5	',QYHVWPHQWV
(Mar.  29,  2012),  available  at  
http://www.whitehouse.gov/sites/default/files/microsites/ostp/big_data_press_release_final_2.pdf .    
42  Id.  
43  Id.  The  agencies  are  the  Office  of  Science  and  Technology  Policy,  National  Science  
Foundation,  National  Institutes  of  Health,  Department  of  Defense,  Department  of  Energy,  and  U.S.  
Geological  Survey.  
44  Id.  7KHLQWHUQDWLRQDO*HQRPH3URMHFW³DLPVWRILQGPRVWJHQHW ic  variants  that  have  
IUHTXHQFLHVRIDWOHDVWSHUFHQWLQWKHSRSXODWLRQVVWXGLHG´$FFRUGLQJWRWKH1DWLRQDO,QVWLWXWHVRI
+HDOWKLWLVWKHZRUOG¶VODUJHVWKXPDQJHQHWLFYDULDWLRQGDWDVHWZLWKWHUDE\WHV±  ³WKHHTXLYDOHQW
of  16  million  file  cabinetVILOOHGZLWKWH[WRUPRUHWKDQVWDQGDUG'9'V´7KHLQIRUPDWLRQLV
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At   the   same   time,   many   federal   entities   are   independently   building   health  
information   databases.45   For   example,   the  Department   of  Veterans  Affairs   (VA)   is  
registering  volunteers   for   its  Million  Veteran  Program  to  construct  a   large  research  
framework   that  will   link   anonymized   blood   samples   and   health   information.46  The  
VA  plans  to  study  how  genes  affect  health  and  disease.47    
The   Centers   for   Medicare   &   Medicaid   Services   created   a   research   database  
called   the  Chronic  Condition  Data  Warehouse.48  The  database  provides  researchers  
with   information   about   Medicare   and  Medicaid   beneficiaries,   claims   for   services,  
and  assessment  data.49    
In   May   of   2008   the   FDA   launched   the   Sentinel   System   in   order   to   facilitate  
post-­PDUNHWLQJ VXUYHLOODQFH DQG HDUO\ GHWHFWLRQ RI PHGLFDO SURGXFWV¶ VDIHW\
problems.50   The   Sentinel   initiative   aims   to   enable   the   FDA   to   access   health  
information  from  100,000,000  individuals.51  Sentinel  is  a  federated  system  that  will  
allow  the  FDA  to  send  queries  concerning  potential  product-­safety  problems  to  data  
holders   such   as   Medicare,   the   VA,   and   major   medical   centers.52   Using   special  
analysis   programs,   the   data   holders   will   assess   their   records   and   send   summary  
responses  to  the  FDA.53    
A   large   number   of   private-­sector   initiatives   are   ongoing   as   well.   Geisinger  
Health   Systems   operates   MedMining,   a   company   that   extracts   EHR   data,   de-­
identifies  it,  and  offers  it  to  researchers.54  The  data  sets  that  MedMining  delivers   to  
LWV FXVWRPHUV LQFOXGH ³ODE UHVXOWV YLWDO VLJQV PHGLFDWLRQV SURFHGXUHV GLDJQRVHV
OLIHVW\OHGDWDDQGGHWDLOHGFRVWV´IURPLQSDWLHQWDQGRXWSDWLHQWIDFLOLWLHV55  
Explorys   has   formed   a   large   healthcare   database   derived   from   financial,  
administrative,   and   medical   records.56   It   has   partnered   with   major   healthcare  
organizations  such  as  the  Cleveland  Clinic  Foundation  and  Summa  Health  System  to  
aggregate   and   standardize   health   information   from   ten   million   patients   and   over  
                                                                                                                                                                                                                                            
available  on  the  Amazon  Web  Services  cloud.  Jeannie  Baumann,  White  House  Initiative  Aims  to  
Improve  Use  of  Large  Digital  Databases  for  R  &  D,  11  MED.  RES.  L.  &  POL¶Y  217,  217-­18  (2012).  
45  See,  e.g.,  Ctrs.  for  Medicare  &  Medicaid  Servs.  (CMS),   About  Chronic  Conditions  Data  
Warehouse,  CHRONIC  CONDITIONS  DATA  WAREHOUSE,  https://www.ccwdata.org/web/guest/about-­
ccw  (last  visited  Oct.  16,  2013);;  )'$¶V6HQWLQHO,QLWLDWLYH,  U.S.  FOOD  &  DRUG  ADMIN.  (Sept.  4,  
2013),  http://www.fda.gov/safety/FDAsSentinelInitiative/ucm2007250.htm;;  Million  Veteran  
Program:  A  Partnership  with  Veterans,  U.S.  DEP¶T  OF  VETERANS  AFFAIRS  (Mar.  6,  2013),  
http://www.research.va.gov/mvp/veterans.cfm.  
46  Million  Veteran  Program,  supra  note  45.    
47  Id.  
48  CMS,  supra  note  45.    
49  Id.  CCW  was  created  pursuant  to  section  723  of  the  Medicare  Modernization  Act  of  2003.  
Medicare  Modernization  Act  of  2003  §  723,  42  U.S.C.  §  1395b-­8  (2006).  
50  Deven  McGraw  et  al.,  A  Policy  Framework  for  Public  Health  Uses  of  Electronic  Health  Data ,  
21(S1)  PHARMACOEPI.  &  DRUG  SAFETY  18,  18  (2012);;  )'$¶V6HQWLQHO,QLWLDWLYH,  supra  note  45.  The  
Sentinel  initiative  was  authorized  by  Congress  in  the  Food  and  Drug  Administration  Amendments  Act  
of  2007.  )'$¶V6Hntinel  Initiative-­Background,  U.S.  FOOD  &  DRUG  ADMIN.  (Sept.  22,  2013),  
http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149340.htm.   
51  McGraw  et  al.,  supra  note  50,  at  18.    
52  Id.  at  19.  See  Hoffman  &  Podgurski,  supra  note  8,  at  131-­33  (discussing  distributed  
databases).  
53  McGraw  et  al.,  supra  note  50,  at  19.  
54  Welcome  to  MedMining,  MEDMINING,  http://www.medmining.com/index.html  (last  visited  
Oct.  13,  2013).  
55  Id.    
56  Explorys  Overview,  EXPLORYS,  https://www.explorys.com/docs/data-­sheets/explorys-­
overview.pdf  (last  visited  Oct.  16,  2013).  




thirty   billion   clinical   events.57   Using   a   cloud-­computing   platform,   it   provides  
customers  with  big  data  to  use  for  research  and  quality  improvement  purposes.58  
The   electronic   Medical   Records   and   Genomics   Network   (eMERGE)   is   a  
consortium   of   five   institutions   with   DNA   repositories   linked   to   EHRs   that   supply  
relevant   clinical   data.59   The   National   Human   Genome   Research   Institute   supports  
eMERGE,   and   the  National   Institute  of  General  Medical  Sciences  provides   it  with  
additional   funding.60   (DFK H0(5*( FHQWHU ZLOO VWXG\ ³WKH UHODWLRQVKLS EHWZHHQ
genome-­ZLGH JHQHWLF YDULDWLRQ DQG D FRPPRQ GLVHDVHWUDLW´ XVLQJ JHQRPH-­wide  
association  analysis.61  A  primary  purpose  of  eMERGE   is   to  develop  approaches   to  
conducting   large-­scale  genetic   research  using  DNA  biobanks   that   are   connected   to  
EHR  systems.62  
The   Distributed   Ambulatory   Research   in   Therapeutics   Network   Institute  
(DARTNet)   is   a   collaboration   among   nine   research   networks,   including   85  
healthcare   organizations   and   over   3,000   clinicians   across   the   United   States.63   The  
first  DARTNet  federated  network,  eNQUIRENet,  was  created  in  2007  and  funded  by  
the  Agency   for  Healthcare  Research   and  Quality.64  DARTNet  members   allow  data  
from  their  EHRs  to  be  captured,  de-­identified,  coded,  standardized,  and  stored   in  a  
Clinical  Data  Repository  (CDR)  within  each  entity  that  also  connects  to  billing,  lab,  
hospital,   and   prescription   databases.65   CDR   data   are   then   transferred   to   a   second  
database   that   makes   de-­identified   information   available   to   researchers   through   a  
secure  web  portal.66    
Other  agencies  and  organizations  are  building  electronic  registries  and  databases  
that  focus  on  specific  disease  categories  in  an  effort  to  promote  research  and  quality  
improvement   endeavors.   These   include   the   Cancer   Biomedical   Informatics   Grid,67  
                                                                                                  
57  Id.  
58  Id.  
59  EMERGE  NETWORK,  http://emerge.mc.vanderbilt.edu/  (last  visited  Oct.  16,  2013).  The  seven  
sites  are:  Group  Health  Cooperative  with  the  University  of  Washington,  Geisinger,  Marshfield  Clinic,  
Mayo  Clinic,  Mount  Sinai  School  of  Medicine,  Northwestern  University,  and  Vanderbilt  University.  
National  Human  Genome  Research  Institute,  Electronic  Medical  Records  and  Genomics  (eMERGE)  
Network,  GENOME.GOV,  http://www.genome.gov/27540473  (last  updated  Aug.  29,  2013).     
60  EMERGE  NETWORK,  supra  note  59;;  Appropriations  Subcommittee  Statement  on  the  Fiscal  
Year  2013  Budget  (Mar.  23,  2012),  NAT¶L  INST.  GEN.  MED.  SCIS.,  
http://www.nigms.nih.gov/About/Budget/Statements/March23_2012.htm.    
61  Catherine  A.  McCarty  et  al.,  The  eMERGE  Network:  A  Consortium  of  Biorepositories  Linked  
to  Electronic  Medical  Records  Data  for  Conducting  Genomic  Studies ,  4  BMC  MED.  GENOMICS  13,  14  
(2011).  
62  Id.  A  recent  study  found  that  data  captured  from  EHRs  could  identify  disease  characteristics  
with  sufficient  accuracy  to  be  used  in  genome-­wide  association  studies.  Kho  et  al.,  supra  note  12,  at  
4-­5.  
63  DARTNET  INSTITUTE:  INFORMING  PRACTICE,  IMPROVING  CARE,  http://www.dartnet.info/  (last  
visited  Oct.  16,  2013);;  About  DARTNet,  DARTNET  INST.,  http://www.dartnet.info/AboutDI.htm  (last  
visited  Oct.  15,  2013).    
64  History  of  the  Organization,  DARTNET  INST.,  http://www.dartnet.info/organization.htm  (last  
visited  Oct.  15,  2013);;  Networks,  DARTNET  INST.,  http://www.dartnet.info/networks.htm  (last  visited  
Oct.  15,  2013).    
65  See  About  DARTNet,  supra  note  63.    
66  Technology,  DARTNET  INST.,  http://www.dartnet.info/Technology.htm  (last  visited  Oct.  15,  
2013).    
67  Software  Tools,  NAT¶L  CANCER  INST.,  
http://www.cancer.gov/clinicaltrials/international/answers/softwaretools   (last  visited  Oct.  15,  2013)  
VWDWLQJWKDWWKHLQLWLDWLYHV¶JRDOLVWR³>E@XLOGRUDGDSWWRROVIRUFROOHFWLQJDQDO\]LQJLQWHJUDWLQJDQG
disseminating  inforPDWLRQDVVRFLDWHGZLWKFDQFHUUHVHDUFKDQGFDUH´  
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the   Interagency   Registry   for   Mechanically   Assisted   Circulatory   Support,68   the  
Extracorporeal   Life   Support   Organization,69   and   the   United   Network   for   Organ  
Sharing.70  
B.  USING  BIOMEDICAL  DATABASES  AND  DATA  NETWORKS  
Large-­scale  biomedical  databases  may  be  used  for  many  purposes.  This  section  
addresses   a   variety   of   ways   in   which   they   are   likely   to   be   used   by   researchers,  
regulators,   public   health   officials,   commercial   entities,   and   lawyers.   As   we   have  
indicated,  biomedical  databases  constitute  an  important  tool  for  medical  researchers.  
They   are   also   used   by   healthcare   providers   who   conduct   quality   assessment   and  
improvement   activities,   and   they   assist   the   FDA   in  monitoring   the   safety   of   drugs  
and   devices   on   an   ongoing   basis.   In   addition,   biomedical   databases   can   support  
public   health   initiatives   and   allow   litigants   in   tort   cases   to   develop   evidence  
concerning  causation  and  harm.  
1.  Scientific  Discovery  
Biomedical   databases   can   enable   researchers   to   conduct   large-­scale  
observational   studies   that  will   fill   existing   knowledge   gaps.  Even   today,   clinicians  
practice   medicine   with   an   unsettling   degree   of   uncertainty.71   According   to   some  
estimates,  doctors  know  that   the   treatments   they  prescribe  will  be  effective   in  only  
twenty   to   twenty-­five  percent  of  cases.72  Database  proponents  believe   that   records-­
based   research   could   contribute   substantially   to   the   resolution   of   these  
uncertainties.73    
Biomedical   databases   could   allow   researchers   to   access   a   vast   quantity   of  
information   about   millions   of   patients   who   are   treated   in   varied   clinical   settings,  
                                                                                                  
68  INTERMACS  Description,  Interagency  Registry  for  Mechanically  Assisted  Circulatory  Support  
(INTERMACS),  http://www.uab.edu/ctsresearch/intermacs/description.htm  (last  visited  Oct.  22,  
2013)  (explaining  thDWDQDO\VLVRIWKHFROOHFWHGGDWDLVH[SHFWHGWRLPSURYHSDWLHQWFDUHDQG³LQIOXHQFH
IXWXUHUHVHDUFK´  
69  ELSO  Registry  Information  Data  Policy,  ECMO  REGISTRY  EXTRACORPOREAL  LIFE  SUPPORT  
ORG.,  http://www.elso.med.umich.edu/DataRequests.html  (last  updated  Oct.  12,  2010)  (providing  
details  concerning  the  collection  of  data  with  most  identifiers  removed,  submission  of  queries,  and  
release  of  query  results  to  members  in  aggregate  form).  
70  Data,  UNITED  NETWORK  FOR  ORGAN  SHARING  (UNOS),  
http://www.unos.org/donation/index.php?topic=data  (last  visited  Oct.  15,  2013)  (discussing  the  
FUHDWLRQRI81HWDQRQOLQHGDWDEDVHV\VWHPWKDW³FRQWDLQVGDWDUHJDUGLQJHYHU\RUJDQGRQDWLRQDQG
WUDQVSODQWHYHQWRFFXUULQJLQWKH8QLWHG6WDWHVVLQFH´   
71  See  David  A.  Hyman  &  Charles  Silver,  The  Poor  State  of  Health  Care  Quality  in  the  U.S.:  Is  
Malpractice  Liability  Part  of  the  Problem  or  Part  of  the  Solution?   90  CORNELL  L.  REV.  893,  952  
(2005)  (REVHUYLQJWKDWD³JUHDWGHDORIXQFHUWDLQW\H[LVWVDERXWWKHµEHVW¶WUeatment  for  particular  
FOLQLFDOFRQGLWLRQVDQGDERXWWKHµEHVW¶ZD\WRSHUIRUPWKRVHWUHDWPHQWV´DQGWKDWWKH³HIILFDF\RI
PRVWPHGLFDOWUHDWPHQWVKDVQHYHUEHHQSURYHQ´:DOWHU)6WHZDUWHWDOBridging  the  Inferential  
Gap:  The  Electronic  Health  Record  and  Clinical  Evidence,  26  HEALTH  AFF.  w181,  w181  (2007)  
GLVFXVVLQJWKH³LQIHUHQWLDOJDS´EHWZHHQ³WKHSDXFLW\RIZKDWLVSURYHGWREHHIIHFWLYHIRUVHOHFWHG
groups  of  patients  versus  the  infinitely  complex  clinical  decisions  required  for  individual  pati HQWV´  
72  John  Carey,  Medical  Guesswork,  BUSINESSWEEK,  May  29,  2006,  at  73,  available  at  
http://www.businessweek.com/stories/2006-­05-­28/medical-­guesswork  (asserting  that  many  physicians  
³VD\WKHSRUWLRQRIPHGLFLQHWKDWKDVEHHQSURYHQHIIHFWLYHLVVWLOORutrageously  low  ±  in  the  range  of  
WR´  
73  Hoffman  &  Podgurski,  supra  note  8,  at  97-­102  (discussing  the  benefits  of  EHR-­based  
research).  




have   diverse   attributes,   and   live   in   different   regions   of   the   country.74   Available  
LQIRUPDWLRQFRXOGLQFOXGHSDWLHQWV¶PHGLFDOKLVWRULHVRYHUWKHLUHQWLUHOLIHWLPHV   The  
data   reviewed   in   database   studies,   consequently,   may   be   far   more   abundant   and  
comprehensive   than   the   data   generated   by   clinical   trials,75   which   are   rigorously  
controlled  and  often  involve  fewer  than  3000  patients.76  Large-­scale  studies  have  the  
potential   to   better   reflect   the   entire   population   and   expose   how   treatments   are  
actually  used  in  a  large  variety  of  medical  facilities.77  They  also  tend  to  enhance  the  
precision  of  statistical  analyses.78  
If  the  researchers  aim  to  show  whether  a  specific  treatment  achieves  the  desired  
benefits,  they  may  reasonably  choose  to  conduct  a  randomized  clinical  trial  to  ensure  
that  uncontrolled  variables  that  influence  outcomes,  such  as  age  or  drug  interactions,  
do   not   confound   the   study.79   However,   observational   studies   may   be   needed   to  
determine  whether  the  results  of  randomized  clinical  trials  that  involved  only  a  few  
thousand  patients  can  be  generalized  to  the  patient  population  at  large  and  to  realistic  
treatment   situations   rather   than   carefully   controlled   ones.80   Furthermore,  
observational  research  based  on  medical  records  will  often  be  sufficient  to  determine  
DWUHDWPHQW¶VDGYHUVHHIIHFWV81  It  is  also  useful  for  generating  and  testing  speculative  
hypotheses   that   could   lead   to   important   insights.82   Observational   studies   are   often  
                                                                                                  
74  Lynn  M.  Etheredge,  A  Rapid-­Learning  Health  System,  26  HEALTH  AFF.  w107,  w111  (2007),  
available  at  http://content.healthaffairs.org/cgi/content/full/26/2w107;;  Hoffman  &  Podgurski,  supra  
note  8,  at  97-­102;;  Louise  Liang,  The  Gap  Between  Evidence  and  Practice,  26  HEALTH  AFF.  w119,  
ZDVVHUWLQJWKDW(+5V³KDYHWKHSRWHQWLDOWRWDNHRYHUZKHUHFOLQLFDOWULDOVand  evidence-­
based  research  leave  off,  by  providing  real-­ZRUOGHYLGHQFHRIGUXJV¶DQGWUHDWPHQWV¶HIIHFWLYHQHVV
DFURVVVXESRSXODWLRQVDQGRYHUORQJHUSHULRGVRIWLPH´see  James  H.  Ware  &  Mary  Beth  Hamel,  
Pragmatic  Trials  ±  Guides  to  Better  Patient  Care?,  364  NEW.  ENG.  J.  MED.  1685,  1685  (2011)  
(discussing  the  shortcomings  of  clinical  trials).  
75  &OLQLFDOVWXGLHVLQYROYH³WKHFROOHFWLRQRIGDWDRQDSURFHVVZKHQWKHUHLVVRPHPDQLSXODWLRQ
of  variables  that  are  assumed  to  affect  the  outcome  of  a  process,  keeping  other  variables  constant  as  
IDUDVSRVVLEOH´BRYAN  F.  J.  MANLY,  THE  DESIGN  AND  ANALYSIS  OF  RESEARCH  STUDIES  1  (1992).  
Thus,  they  involve  actual  experimentation  on  human  subjects  rather  than  just  review  of  their  medical  
records.  
76  Sheila  Weiss  Smith,  Sidelining  Safety±7KH)'$¶V,QDGHTXDWH5HVSRQVHWRWKH,20,  357  NEW.  
ENG.  J.  MED.  960,  961  (2007).  
77  See  John  P.A.  Ioannidis,  Why  Most  Published  Research  Findings  Are  False ,  2  PLOS  MED.  696,  
700  (2005).  
78  See  David  Moher  et  al.,  Statistical  Power,  Sample  Size,  and  Their  Reporting  in  Randomized  
Controlled  Trials,  272  J.  AM.  MED.  ASS¶N  122,  122-­24  (1994).  
79  Hoffman  &  Podgurski,  supra  note  8,  at  98-­99;;  Jan  P.  Vandenbroucke,  The  HRT  Controversy:  
Observational  Studies  and  RCTs  Fall  in  Line ,  373  LANCET  1233,  1234  (2009).  
80  Stuart  L.  Silverman,  From  Randomized  Controlled  Trials  to  Observational  Studies,  122  AM.  J.  
MED.  H[SODLQLQJWKDW³>R@EVHUYDWLRQDOVWXGLHVPD\EHDQLPSRUWDQWDGGLWLRQWRWKH
FOLQLFLDQ¶VUHVRXUFHVE\FRPSOHPHQWLQJUDQGRPL]HGFRQtrolled  trial  data  with  information  on  efficacy,  
safety,  and  patient  compliance  in  a  population  of  real-­ZRUOGSDWLHQWV´6WHZDUWHWDOsupra  note  71,  
DWVWDWLQJWKDWDQDO\VLVRI(+5GDWDVKRXOGKHOSEULGJHWKH³LQIHUHQWLDOJDS´EHWZHHQ³WKHSDXFLW\
of  what  is  proved  to  be  effective  for  selected  groups  of  patients  versus  the  infinitely  complex  clinical  
GHFLVLRQVUHTXLUHGIRULQGLYLGXDOSDWLHQWV´  
81  Jan  P.  Vandenbroucke,  Observational  Research,  Randomised  Trials,  and  Two  Views  of  
Medical  Science,  5  PLOS  MED.  339,  341  (2008),  available  at  
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0050067  (explaining  
that  adverse  effects  are  generally  unexpected  and  unpredictable,  and  therefore  are  not  subject  to  
³FRQIRXQGLQJE\LQGLFDWLRQ´  and  can  be  determined  through  observational  studies).  See  infra  notes  
244-­247  and  accompanying  text  for  discussion  of  confounding  by  indication.   
82  Vandenbroucke,  supra  QRWHDWDVVHUWLQJWKDW³>P@XFKJRRGFDQFRPHIURPJRLQJ
down  the  wrong  alley  and  detecting  why  it  is  wrong,  or  playing  with  a  seemingly  useless  hypothesis;;  
WKHUHDOEUHDNWKURXJKPLJKWFRPHIURPWKDWH[SHULHQFH´   
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less   costly   and   time-­consuming   than   experimental   research,   especially   when  
researchers  obtain  the  required  data  from  existing  databases.83  
The   benefits   of   observational   studies   are   illustrated   by   the   highly   publicized  
controversy   concerning   an   alleged   association   between   vaccination   and   autism.   In  
1998,  Dr.  Andrew  J.  Wakefield  and  colleagues  published  a  study  in  the  Lancet  that  
suggested   a   link   between   autism   and   the   measles,   mumps,   rubella   (MMR)  
vaccination.84   The   findings   were   based   on   testing   of   twelve   children   with  
developmental  disorders.85  ,QPRVWRI WKHDXWKRUV³UHWUDFWHG WKH LQWHUSUHWDWLRQ
placed   upon   these   fiQGLQJV LQ WKH SDSHU´86   after   large-­scale   observational   research  
involving   the   review   of   hundreds   of   records   of   autistic   children   in   the   United  
Kingdom   found   no   causal   association   between   the   MMR   vaccine   and   autism.87  
Consequently,  the  Centers  for  Disease  Control  and  Prevention  (CDC)  now  reassures  
the  public  on  its  website  that  there  is  no  link  between  autism  and  vaccines.88    
For   purposes   of   genetic   research,   EHRs   can   be   coupled  with   genetic   samples  
and  data  so  that  analysts  can  obtain  detailed  and  comprehensive  characterizations  of  
study  subjects.89  An  increasingly  common  form  of  big-­data  observational  research  is  
genome-­wide   association   studies   (GWASs).90   GWASs   compare   the   DNA   of  
individuals   with   a   particular   disease   or   condition   to   the   DNA   of   unaffected  
individuals   in   order   to   find   the   genes   involved   in   the   disease.91   A   government  
website  catalogues  published  GWASs  and  on  October  24,  2013,  listed  1,727  studies  
that  had  been  conducted  since  2005.92  Critics  have  noted  that  although  GWASs  led  
to   the   discovery   of   many   genetic   variants   that   are   statistically   associated   with  
disease;;  thus  far,  most  of  the  variants  appear  to  have  a  minimal  effect  on  disease  and  
                                                                                                  
83  Kjell  Benson  &  Arthur  J.  Hartz,  A  Comparison  of  Observational  Studies  and  Randomized,  
Controlled  Trials,  342  NEW  ENG.  J.  MED.  1878,  1878  (2000)  PHQWLRQLQJ³JUHDWHUWLPHOLQHVV´DVDQ
advantage  of  observational  studies);;  David  Kaelber  et  al.,  Patient  Characteristics  Associated  with  
Venous  Thromboembolic  Events:  A  Cohort  Study  Using  Pooled  Electronic  Health  Record  Data ,  19  J.  
AM.  MED.  INFORMATICS  ASS¶N  965,  966  (2012);;  Friedrich  K.  Port,  Role  of  Observational  Studies  
Versus  Clinical  Trials  in  ESRD  Research,  57  KIDNEY  INT¶L  S3,  S4  (2000),  available  at  
http://www.nature.com/ki/journal/v57/n74s/full/4491615a.html.  For  further  details  about  the  benefits  
of  observational  studies,  see  Hoffman  &  Podgurski,  supra  note  8,  at  97-­102.  
84  Andrew  J.  Wakefield  et  al.,  Ileal-­Lymphoid-­Nodular  Hyperplasia,  Non-­Specific  Colitis,  and  
Pervasive  Developmental  Disorder  in  Children,  351  LANCET  637,  641  (1998).  
85  Id.  at  637.  
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explain  only  a  small  percentage  of  heritability.93  Others  assert  that  many  GWASs  to  
date  have  been  compromised  by  serious  design  flaws.94  However,  GWASs  remain  an  
important   scientific   endeavor   and   will   likely   lead   to   significant   discoveries   in   the  
future.  
A   different   method   of   scanning   the   genome   is   genome-­wide   linkage   studies  
(GWLSs).   Researchers   perform   GWLSs   when   they   are   focusing   on   biologically  
related   individuals  and  a  phenotype,  such  as  breast  cancer,   that  some  but  not  all  of  
the   family  members   have.95  Based   on   patterns   of   correlation   between   alleles96   and  
disease   found  within   families,   researchers   attempt   to  detect   broad  DNA   regions   in  
which  disease  susceptibility  loci  are  most  likely  to  be  found.97    
The   Federal   Government   and   many   medical   experts   have   embraced   the  
objective  of   conducting   extensive   comparative   effectiveness   research   (CER).98  The  
Patient   Protection   aQG $IIRUGDEOH &DUH $FW RI  GHILQHV &(5 DV ³UHVHDUFK
evaluating  and  comparing  health  outcomes  and  the  clinical  effectiveness,  risks,  and  
benefits  of  2  or  more  medical   treatments,   services,   and   items   .   .   .   .´99  CER  can  be  
conducted   in   part   through   observational   studies,   which   can   be   particularly  
illuminating   because   they   reflect   actual   usage   of   treatments.100   The   outcomes   of  
CER   and   other   observational   studies   may   ultimately   enable   the   healthcare  
community  to  alleviate  human  suffering  more  effectively,  reduce  medical  costs,  and  
VDYHSDWLHQWV¶OLYHV101  
2.  Quality  Assessment  and  Improvement  
Healthcare  providers  routinely  collect  quality  measures  concerning  the  services  
they   provide.102   Increasingly,   they   will   use   EHR   databases   to   obtain   necessary  
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Medical   facilities   and   government   authorities   conduct   a   variety   of   oversight  
activities.  Providers  may  seek  data  for  internal  quality  assessment  purposes  in  order  
to   judge   the   success   of   particular   initiatives.104   Insurers   may   require   facilities   to  
submit   process   and   outcome   information   in   the   context   of   pay-­for-­performance  
programs.105   In   addition,   the   Centers   for   Medicare   and  Medicaid   Services   (CMS)  
and  many  state  governments  require  quality  measurements  and  public  reporting.106  A  
SULPHH[DPSOH LV&06¶V+RVSLWDO&RPSDUHZKLFK IHDWXUHVSXEOLFO\-­available  data  
about  the  quality  of  care  at  over  4000  hospitals.107  
3.  Post-­Marketing  Surveillance  of  Drugs  and  Devices  
EHR   databases   could   assist   the   FDA   in   regulating   drugs   and   devices.108   The  
Food  and  Drug  Administration  Amendments  Act  of  2007  (FDAAA)109  expanded  the  
)'$¶V DXWKRULW\ WR PRQLWRU PHGLFDO SURGXFWV DIWHU WKH\ KDYH EHHQ DSSURYHG DQG
deployed   in   the   marketplace.110   Evidence   concerning   drug   safety   in   the   post-­
marketing   period   will   be   developed   in   significant   part   through   observational  
studies.111   Such   studies   will   be   made   possible   through   the   Sentinel   System,   the  
national  health  data  network  discussed  previously.112  
While   clinical   trials   constitute   the   gold   standard   for   purposes   of   FDA   drug  
approval,113   they  have   important  weaknesses   that  have  been  documented  elsewhere  
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studies  would  be  inadequate).  
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clinical  trials  have  been  considered  by  many  to  be  the  only  reliable  source  for  information  in  health  
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in   the   literature.114  7KHVH LQFOXGH WKH VWXGLHV¶ UHODWLYHO\ VKRUW GXUDWLRQ VPDOO VL]H
and   limited   generalizability.115   Congress   thus   opted   to   supplement   pre-­approval  
clinical  trials  with  post-­marketing  surveillance.  Emerging  evidence  concerning  drug  
safety  problems  may  not   only  be   illuminating   for  physicians,   but   also  may   lead   to  
legal   interventions.  The  FDA  may   implement   regulatory  measures   to  manage  drug  
risks  through  Risk  Evaluation  and  Mitigation  Strategies,116  or  it  may  require  changes  
in  drug  labeling.117  In  cases  of  imminent  public  danger,  the  FDA  may  also  withdraw  
or   suspend   its   approval   of   the   drug118   or   ask   manufacturers   to   remove   drugs  
voluntarily   from   the   market,   as   the   Agency   did   in   2010   in   the   case   of   the   pain  
medication  propoxyphene  (Darvocet).119  
Like   the  United   States,   the   European  Union   is   pursuing   initiatives   to   enhance  
drug  safety  monitoring.120  7KH(XURSHDQ&RPPLVVLRQKDVIXQGHGWKH³([SORULQJDQG
Understanding  Adverse  Drug  Reactions   by   Integrative  Mining   of  Clinical   Records  
DQG %LRPHGLFDO .QRZOHGJH´ SURMHFW (8-­ADR),   which   launched   in   2008.121   EU-­
$'5 LV GHVLJQHG WR H[SORLW GDWD IURP RYHU WKLUW\ PLOOLRQ SDWLHQWV¶ (+5V LQ WKH
Netherlands,   Denmark,   the   United   Kingdom,   and   Italy.122   Experts   will   use  
computational  techniques  to  analyze  EHRs  in  order  to  identify  possible  drug-­related  
adverse  events  that  signal  a  need  for  further  scrutiny.123  
7KXVIDUWKH8QLWHG6WDWHV¶6HQWLQHO6\VWHPSURMHFWVKDYHIRFXVHGRQGUXJVEXW
this  data  network  or  other  electronic  resources  could  be  used   to  monitor  devices  as  
well.124  Medical  devices  are  often  complex  and  delicate,  and  failures  in  any  of  their  
many  components  can  significantly  endanger  patient  lives.125  One  example  of  such  a  
failure  is  the  erosion  of  insulation  in  leads  for  implantable  cardioverter-­defibrillators  
manufactured  by  St.  Jude  Medical  that  were  recalled  in  2011.126  Commentators  have  
called   for   intensified   post-­marketing   surveillance   of   devices   through   analysis   of  
electronically  available  data.127  Registries  of  high-­risk  medical  devices,  such  as   the  
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Interagency   Registry   for   Mechanically   Assisted   Circulatory   Support  
(INTERMACS),  are  a  valuable  tool  because  they  collect  clinical  data  about  patients  
after   their   devices  have  been   implanted.128   Ideally,   automated   surveillance   systems  
would  trigger  alerts  if  the  frequency  of  adverse  events  related  to  a  device  exceeded  a  
designated   threshold129   so   that   healthcare   providers   could   react   appropriately   and  
prevent  further  harm  to  patients.  
4.  Public  Health  Initiatives  
Federal   regulations   and   public   health   projects   demonstrate   that   biomedical  
databases  will  also  be  used  to  promote  public  health  goals.  Healthcare  providers  who  
wish   to   receive   government   incentive   payments   to   support   EHR   system  
implementation  effRUWVPXVWFRPSO\ZLWK³0HDQLQJIXO8VH´UHJXODWLRQVWKDWVSHFLI\
the  EHR  functions  they  must  be  able  to  perform.130  These  include  sending  certain  lab  
results  and  reports  electronically   to  public  health  agencies  and  providing  electronic  
information   to   immunization   registries.131   Public   health   authorities   are   meant   to  
collect   the   submitted   information   in   databases   and   use   it   to   conduct   disease  
surveillance  and  respond  to  public  health  threats.132    
Some  public  health  entities  have  already  launched  programs  that  use   electronic  
data.133  Examples  are  programs  that  track  information  about  vaccine-­related  adverse  
events,  sexually  transmitted  diseases  (STDs),  and  HIV/AIDS.134  
The  Centers  for  Disease  Control  and  Prevention  is  collaborating  with  eight  large  
health   maintenance   organizations   to   detect   adverse   events   associated   with  
vaccinations.135  The  Vaccine  Safety  Datalink  (VSD)  has  access  to  large  clinical  data  
repositories   that   are   linked   together   and   provide   information   about   almost   2.5  
percent  of  the  U.S.  population.136  Information  garnered  by  the  VSD  could  potentially  
lead  to  changes  in  state  vaccination  laws.137  
New  York  City  implemented  an  EHR  system  in  2004-­05  for  its  ten  Department  
of  Health   and  Mental  Hygiene   public   clinics   that   treat   patients   with   STDs.138   The  
                                                                                                  
128  Resnic  &  Normand,  supra  note  119,  at  876;;  Welcome  to  INTERMACS,  UAB  SCHOOL  MED.,  
http://www.uab.edu/medicine/intermacs/  (last  visited  Oct.  22,  2013).   
129  Resnic  &  Normand,  supra  note  119,  at  877.  
130  Leslie  Lenert  &  David  Sundwall,  Public  Health  Surveillance  and  Meaningful  Use  
Regulations:  A  Crisis  of  Opportunity,  102  AM.  J.  PUB.  HEALTH  e1,  e1  (2012).  
131  Resnic  &  Normand,  supra  note  124,  at  876;;  Welcome  to  INTERMACS,  supra  note  128.    
132  Lenert  &  Sundwall,  supra  note  130,  at  e1-­e2  (arguing  that  the  infrastructure  of  contemporary  
public  health  authorities  is  inadequate  for  the  task  of  receiving  and  processing  such  large  amounts  of  
information).  
133  Sharona  Hoffman  &  Andy  Podgurski,  Big  Bad  Data:  Law,  Public  Health,  and  Biomedical  
Databases,  41  J.L.  MED.  &  ETHICS  56,  56  (2013).  
134  See,  e.g.,  eHealth  in  Public  Health,  CAL.  DEPT.  HEALTH,  
http://www.cdph.ca.gov/data/informatics/Pages/eHealth.aspx  (last  visited  Oct.  25,  2013);;   Disease  
Prevention,  MONROE  CNTY.,  http://www2.monroecounty.gov/health-­diseases.php  (last  visited  Oct.  25,  
2013);;  HIV/AIDS  Program  Home,  IOWA  DEPT.  PUB.  HEALTH,  
http://www.idph.state.ia.us/HivStdHep/HIV-­AIDS.aspx?prog=Hiv&pg=HivHome  (last  visited  Oct.  
25,  2013).  
135  Brian  Hazlehurst  et  al.,  Detecting  Possible  Vaccine  Adverse  Events  in  Clinical  Notes  of  the  
Electronic  Medical  Record,  27  VACCINE  2077,  2077  (2009).  
136  Id.  at  2081.  
137  See  State  Vaccination  Requirements,  CTRS.  FOR  DISEASE  CONTROL  &  PREVENTION,  
http://www.cdc.gov/vaccines/vac-­gen/laws/state-­reqs.htm  (last  modified  Sept.  30,  2011);;  State  Law  
and  Vaccine  Requirements,  NAT¶L  VACCINE  INFO.  CTR.,  http://www.nvic.org/vaccine-­laws/state-­
vaccine-­requirements.aspx  (last  visited  Oct.  22,  2013).  
138  See  Rachel  Paneth-­Pollak  et  al.,  Using  STD  Electronic  Medical  Record  Data  to  Drive  Public  
Health  Program  Decisions  in  New  York  City,  100  AM.  J.  PUB.  HEALTH  586,  586  (2010).  




EHRs  haYHHQDEOHGWKH'HSDUWPHQWWRDQDO\]HWKHFLW\¶VFOLQLFDOVHUYLFHV139  Several  
evaluations  led  the  city  to  alter  its  policies  in  order  to  increase  opportunities  for  STD  
testing  and  access  to  care.140    
The   Louisiana   Public   Health   Information   Exchange   (LaPHIE)   links   statewide  
public   health   surveillance   information  with   individual   EHR   data.141   LaPHIE   alerts  
clinicians   when   an   HIV-­positive   patient   who   has   not   received   HIV   care   for   over  
twelve  months   presents   at   any   healthcare   facility   for   any   reason,   so   that   providers  
may  pursue  HIV  care  with  that  patient.142  Such  information  exchange  networks  can  
constitute   a   valuable   tool   for   combating   infectious   disease   and   assist   states   in  
fulfilling  their  public  health  responsibilities.143  
5.  Litigation  
If   databases   of   de-­identified   EHR   information   become   publicly   available   for  
non-­clinical   purposes,   litigants   who   seek   to   prove   causation   or   harm   in   mass   tort  
cases   may   mine   them   for   evidence.144   Several   such   databases   already   exist.   For  
example,   California,   Texas,   and   Vermont   have   databases   of   inpatient   hospital  
discharge  data.145  Selected  datasets  that  do  not  directly  identify  patients  but  include  
diagnoses,  treatments,  drug  intake,  and  other  details  are  available  for  purchase  by  the  
public.146   Private   sector   enterprises,   such   as   MedMining   and   Strategic   Healthcare  
Programs,  also  offer  requestors  access  to  their  health  information  databases.147    
Data  availability  has  been  promoted  in  academic  circles  as  well.  Professor  Marc  
Rodwin  argues  that  patient  data  should  routinely  be  treated  as  public  property.148  He  
posits  that  federal  law  should  require  clinicians,  hospitals,  and  insurers  to  report  de-­
identified   patient   data   to   public   authorities   who   would   create   aggregate   databases  
that  would  be  available  to  private  entities,  subject  to  public  oversight.149    
Litigants  have  already  used  epidemiological  evidence   in  many  mass   tort  cases,  
VXFK DV WKRVH DOOHJLQJ KDUP IURP ³DVEHVWRV%HQGHFWLQ HOHFWUR-­magnetic   radiation,  
,8'V VLOLFRQH LPSODQWV DQG WREDFFR SURGXFWV´150   Epidemiological   data   is   most  
                                                                                                  
139  Id.    
140  Id.  at  589.  
141  Jane  Herwehe  et  al.,  Implementation  of  an  Innovative,  Integrated  Electronic  Medical  Record  
(EMR)  and  Public  Health  Information  Exchange  for  HIV/AIDS ,  19  J.  AM.  MED.  INFORMATICS  ASS¶N  
448,  448  (2012).  
142  Id.  at  448-­49.  
143  Id.  at  452  (Louisiana  has  developed  similar  alerts  for  tuberculosis  patients  in  need  of  follow-­
up  care.).  
144  Sharona  Hoffman  &  Andy  Podgurski,  Finding  A  Cure:  The  Case  for  Regulation  and  
Oversight  of  Electronic  Health  Record  Systems,  22  HARV.  J.L.  &  TECH.  103,  124  (2008).  
145  See  Inpatient  Hospital  Discharge  Data,  CAL.  DIABETES  PROGRAM,  
http://www.caldiabetes.org/content.cfm?contentID=487&CategoriesID=31&CFID=5020870&CFTOK
EN=92167121  (last  visited  Oct.  22,  2013);;  Health  Care  Information  User  Manual,  Texas  Hospital  
Inpatient  Discharge  Public  Use  Data  File ,  TEX.  DEP¶T  STATE  HEALTH  SERVS.  
http://www.dshs.state.tx.us/thcic/hospitals/Inpatientpudf.shtm  (last  updated  Aug.  12,  2013);;  VUHDDS  
Frequently  Asked  Questions,  VT.  DEP¶T  HEALTH,  http://healthvermont.gov/research/hospital-­
utilization/VHUR_FAQS.aspx  (last  visited  Oct.  25,  2013).     
146  See  Herwehe  et  al.,  supra  note  141,  at  452;;  Marc  A.  Rodwin,  Patient  Data:  Property,  Privacy  
&  the  Public  Interest,  36  AM.  J.L.  &  MED.  586,  615  (2010).  See  also  Hoffman  &  Podgurski,  supra  
note  8,  at  95-­97,  104-­07,  128-­31  (discussing  de-­identification  of  data).  
147  See  Welcome  to  MedMining,  MEDMINING,  http://www.medmining.com/index.html  (last  
visited  Oct.  22,  2013);;  Request  Data,  STRATEGIC  HEALTHCARE  PROGRAMS,  LLC,  
https://www.shpdata.com/company/requestdata.aspx  (last  visited  Oct.  22,  2013).  
148  Rodwin,  supra  note  146,  at  590.  
149  Id.  at  589.  
150  FAIGMAN  ET  AL.,  supra  note  20,  at  339-­40.  
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often   employed   with   respect   to   causation,   and   it   is   not   unusual   for   the   courts   to  
accept   it   as   persuasive.151   In   the   future,   observational   studies   based   on   biomedical  
databases  may  frequently  aid  in  developing  compelling  epidemiological  evidence.  
While   plaintiffs   will   attempt   to   prove   causation   through   database   analysis,  
GHIHQGDQWVPD\XVHWKHVDPHWRROWRXQGHUPLQHSODLQWLIIV¶FODLPVRIFDXVDWLRQ 152  For  
H[DPSOHGHIHQVHFRXQVHOFRXOGDUJXH WKDWSODLQWLIIV¶ LOOQHVVHVDUH OLQNHG WRJHQHWLF
IDFWRUV UDWKHU WKDQ WR GHIHQGDQWV¶ Sroducts.153  Researchers   have   found   that   genetic  
variants   influence   conditions   that   are  often   at   the   center   of   legal   disputes.  Genetic  
YDULDQWV PD\ LQFUHDVH LQGLYLGXDOV¶ OLNHOLKRRG RI EHLQJ KHDY\ VPRNHUV 154   of  
developing  lung  cancer  or  chronic  obstructive  pulmonary  disease,155  and  of  suffering  
from   carpal   tunnel   syndrome.156   Commentators   predict   that   defendants   will  
LQFUHDVLQJO\DWWHPSW WRGHIHDWSODLQWLIIV¶DOOHJDWLRQVE\DUJXLQJ WKDW ³WKHJHQHVGLG
LW´157    
The  Burlington  Northern  and  Santa  Fe  Railway  Company  attempted  to  use  this  
approach   more   than   a   decade   ago.158   When   several   employees   claimed   that   they  
suffered   from   carpal   tunnel   syndrome   (CTS)   caused   by   their   work,   Burlington  
Northern  required  them  to  provide  a  blood  sample  that  would  be  tested  for  a  genetic  
marker   believed   to   be   associated   with   CTS.159   In   addition,   a   study   of   tobacco  
PDQXIDFWXUHUV¶ GHIHQVHV LQ SHUVRQDO LQMXU\ FDVHV EURXJKW E\ VPRNHUV ZLWK FDQFHU
revealed   that   in   at   least   one   case,  Mehlman   v.  Philip  Morris,   Inc.,   a  manufacturer  
                                                                                                  
151  Id.  at  341;;  Norris  v.  Baxter  Healthcare  Corp.,  397  F.3d  878,  882  (10th  Cir.  2005)  (noting  that  
³WKHERG\RIHSLGHPLRORJ\ODUJHO\ILQGVQRDVVRFLDWLRQEHWZHHQVLOLFRQHEUHDVWLPSODQWVDQGLPPXQH
V\VWHPGLVHDVHV´  
152  Sharon  Milberger  et  al.,  7REDFFR0DQXIDFWXUHUV¶'HIHQFH$JDLQVW3ODLQWLIIV¶&ODLPVRI
Cancer  Causation:  Throwing  Mud  at  the  Wall  and  Hoping  Some  of  It  Will  Stick ,  15  TOBACCO  
CONTROL  iv17,  iv22  (Supp.  IV  2006).  
153  See  Bowen  v.  E.I.  Du  Pont  De  Nemours  &  Co.,  No.  Civ.A.  97C-­06-­194  CH,  2005  WL  
1952859,  at  *4  (Del.  Super.  Ct.  2005)  (involving  a  claim  by  defendant  that  the  injuries  and  condition  
LQTXHVWLRQ³FRQVWLWXWH&+$5*(6\QGURPHZKLFKLVJHQHUDOO\WKRXJKWWREHJHQHWLFDVRSSRVHGWR
HQYLURQPHQWDOLQRULJLQ´  
154  Nancy  L.  Saccone  et  al.,  Multiple  Independent  Loci  at  Chromosome  15q25.1  Affect  Smoking  
Quantity:  a  Meta-­Analysis  and  Comparison  with  Lung  Cancer  and  COPD ,  8  PLOS  GENETICS  1,  3  
(2010);;  Thorgeir  E.  Thorgeirsson  et  al.,  Sequence  Variants  at  CHRNB3-­CHRNA6  and  CYP2A6  Affect  
Smoking  Behavior,  42  NATURE  GENETICS  448,  448  (2010).    
155  Paul  Brennan  et  al.,  Genetics  of  Lung-­Cancer  Susceptibility,  12  LANCET  ONCOLOGY  399,  403-­
04  (2011);;  Peter  Broderick  et  al.,  Deciphering  the  Impact  of  Common  Genetic  Variation  on  Lung  
Cancer  Risk:  A  Genome-­Wide  Association  Study,  69  CANCER  RES.  6633,  6633  (2009);;  Michael  H.  Cho  
et  al.,  A  Genome-­Wide  Association  Study  of  COPD  Identifies  A  Susceptibility  Locus  on  Chromosome  
19q13,  21  HUMAN  MOLECULAR  GENETICS  947,  948-­49  (2012);;  Saccone  et  al.,  supra  note  154,  at  3;;  
Thorgeirsson  et  al.,  supra  note  154,  at  448.    
156  Alan  J.  Hakim  et  al.,  The  Genetic  Contribution  to  Carpal  Tunnel  Syndrome  in  Women:  A  Twin  
Study,  47  ARTHRITIS  &  RHEUMATISM  275,  277  (2002);;  Santiago  Lozano-­Calderon  et  al.,  The  Quality  
and  Strength  of  Evidence  for  Etiology:  Example  of  Carpal  Tunnel  Syndrome ,  33A  J.  HAND  SURGERY  
AM.  525,  532-­33  (2008).  
157  Gold,  supra  note  23,  at  412;;  Diane  E.  Hoffman  &  Karen  H.  Rothenberg,  Judging  Genes:  
Implications  of  the  Second  Generation  of  Genetic  Tests  in  the  Courtroom,  66  MD.  L.  REV.  858,  867  
(2007);;  Gary  E.  Marchant,  Genetic  Data  in  Toxic  Tort  Litigation,  14  J.L.  &  POL¶Y  7,  12  (2006);;  Susan  
Poulter,  Genetic  Testing  in  Toxic  Injury  Litigation:  The  Path  to  Scientific  Certainty  or  Blind  Alley?,  
41  JURIMETRICS  J.  211,  217-­20  (2001).  
158  EEOC  v.  Burlington  N.  and  Santa  Fe  Ry.  Co.,  No.  02-­C-­0456,  2002  WL  32155386,  at  *1  (E.  
D.  Wis.  2002).    
159  Id.  The  case  settled  before  trial.  




FLWHG ³KHUHGLW\´ DV RQH RI WKH IDFWRUV WKDW FDXVHG WKH SODLQWLII¶V FDQFHU160   A   jury  
found  against  the  plaintiff  in  2001.161  
It   is  also  possible   that   self-­appointed  watchdogs  may  mine  public  databases   to  
determine  whether   exposure   to  particular   products  or   substances   results   in   adverse  
health   consequences.   Based   on   their   findings,   they   could   publicize   supposed  
problems,   demand   government   intervention   or   encourage   lawyers   to   initiate  
litigation.  
III.  LIMITATIONS  OF  BIOMEDICAL  DATABASES  
Biomedical   databases   constitute   a  potentially   invaluable   research   resource,  but  
researchers,  analysts,  and  other  stakeholders  must  appreciate  that  existing  EHRs  and  
genomic   data   often   contain   errors,   are   incomplete,   or   suffer   from   other  
shortcomings.   While   any   collection   of   research   data   may   be   contaminated   by  
inaccuracies,   biomedical   databases  may   be   particularly   flawed.  The   information   in  
EHRs  is  initially  collected  for  clinical  and  billing  purposes,  and  thus  it  might  be  ill -­
suited  for  research.162  Moreover,  the  sheer  volume  of  information  contained  in  large  
biomedical   databases163   and   the   complex   analytical   methods   and   tools   required   to  
conduct   large-­scale   observational   studies164   create   myriad   opportunities   for   the  
introduction  of  errors  and  omissions.  While  improved  technology  may  remedy  many  
database   shortcomings   in   the   future,165   these   deficiencies   are   currently   of   serious  
concern.  This  section  examines  a  variety  of  potential  data  quality  problems.   
A.  DATA  ENTRY  ERRORS  
EHR   databases   may   be   tainted   by   data   entry   errors.   Digitization   can   prevent  
some  data   quality  problems,   such   as   those   associated  with   illegible  handwriting, 166  
but   it   does   not   remove   the   risk   that   entries   in   patient   records   will   be   incorrect.  
Inaccurate   clinical   data   will   become   inaccurate   research   data   if   the   EHRs   are  
imported   to   research   databases   or   are   accessible   to   investigators   through   federated  
systems.  
Clinicians   who   enter   data   into   records   can   easily   invert   numbers   or   mistype  
words,   select   wrong   items   from   a   menu,   check   the   wrong   box,   obtain   inaccurate  
information   from   patients,   and   make   other   data   entry   mistakes.167   A   variety   of  
researchers   and   commentators   have   recognized   that   computerization   itself   can  
FRQWULEXWH WR HUURUV LQYROYLQJ ³ORVV RI FRQFHQWUDWLRQ VOLS RI WKH ILQJHU RU
                                                                                                  
160  Milberger  et  al.,  supra  note  152,  at  iv22  tbl.  6;;  Mehlman  v.  Philip  Morris,  Inc.,  No.  L-­1141-­
99,  (Sup.  Ct.  N.J.  filed  Feb.  4,  1999),  available  at  http://legacy.library.ucsf.edu/tid/ekz52d00/pdf  
(Legacy  Tobacco  Documents  Library).    
161  Milberger  et  al.,  supra  note  152,  at  iv22;;  Stephen  D.  Sugarman,  Address  at  the  Robert  Wood  
Johnson  Foundation's  SAPRP  Conference:  Tobacco  Litigation  Update  (revised  as  of  November  5,  
2001)  2  (Nov.  14,  2001),  available  at  
http://www.law.berkeley.edu/sugarman/tobacco_litigation_upate_october_2001_.doc.  The  decedent,  
SODLQWLII¶VZLIHKDGVWRSSHGVPRking  30  years  before  her  death.  
162  See  infra  Part  III.C.  
163  See  supra  Part  II.A.  (discussing  database  initiatives).  
164  See  infra  Parts  III.D.,  IV  (discussing  software  failures  and  the  challenges  of  causal  inference).   
165  See  infra  Part  VI.A.  
166  WIN  PHILLIPS  &  YANG  GONG,  HUMAN  COMPUTER  INTERACTION:  INTERACTING  IN  VARIOUS  
APPLICATION  DOMAINS  589,  591  (Julie  A.  Jacko  ed.,  2009).    
167  Ancker  et  al.,  supra  note  40,  at  61;;  Botsis  et  al.,  supra  note  40,  at  3-­4;;  Sharona  Hoffman  &  
Andy  Podgurski,  E-­Health  Hazards:  Provider  Liability  and  Electronic  Health  Record  Systems,  24  
BERKELEY  TECH.  L.J.  1523,  1544-­45  (2009)  (discussing  input  errors).  
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GLVWUDFWLRQ´168   and   some   of   these   errors   are   unique   to   digitized   rather   than   paper  
records.  For  example,   in  order  to  save  time,  clinicians  may  copy  and  paste  relevant  
narrative  from  prior  visit  notes  and  place  it  in  the  wrong  location  in  the  chart  or  fail  
to   carefully   edit   or   update   it.169   They   may   also   neglect   to   save   notes   in   unclosed  
charts,  or  they  may  misinterpret  lab  results  that  are  displayed  in  a  confusing  fashion  
DQGFRQVHTXHQWO\PDNHLQFRUUHFWQRWHVDERXWSDWLHQWV¶SURJUHVV170    
Several   studies   have   attempted   to   estimate   error   rates   in   EHRs.   A   study   of   a  
number  of   research  databases  containing   information  about  oncology  patients  at  an  
academic  medical  center   found  error  rates  of  2.3-­26.9%.171  Errors  were  attributable  
to  data  entry  mistakes,  misinterpretation  of  hard-­copy  documents  when  information  
was   typed   into   the   database,   and   perpetuation   of   errors   that  were   contained   in   the  
original  paper  documents  and  then  copied  during  the  data  entry  process.172  Another  
publication  found  an  average  error  rate  of  9.76%.173  A  small  study  involving  twenty-­
five  Israeli  physicians  revealed   that  over  sixty  percent  of  participants  admitted   that  
they  had  PLVW\SHGLQIRUPDWLRQHQWHUHGLQIRUPDWLRQLQWRWKHZURQJSDWLHQWV¶FKDUWV
or  selected  an  incorrect  item  from  an  electronic  menu  of  choices,  though  pharmacists  
often  served  as  a  safeguard  against  actual  treatment  mistakes.174  
A   different   study   highlighted   the   frequency   of   medication   discrepancies   in  
hospitals.175   The   study   identified   2066   medication   discrepancies   relating   to   180  
patients,  of  which  939  were  unintentional  and  therefore  constituted  errors.176  Among  
the  errors,  257  instances  had  the  potential  to  harm  patients.177  The  majority  (72%)  of  
errors  stemmed  from  mistakes  made  while  taking  preadmission  medication  histories,  
and   the   remainder   was   caused   by   failure   to   reconcile   medication   history   with  
discharge  orders.178  The  most  common  reasons  for  potentially  dangerous  errors  were  
WKH SDWLHQWV¶ RZQ FRQIXVLRQ DERXW WKH PHGLFDWLRQV WKH\ WRRN EHIRUH KRVSLWDO
admission,   medication   changes   during   hospitalization,   and   intern   assistance   with  
recording  patient  histories.179  
                                                                                                  
168  Robert  E.  Hirschtick,  Copy-­and-­Paste,  295  J.  AM.  MED.  ASS¶N  2335,  2335-­36  (2006);;  Sheila  
Roszell  &  Cheryl  Stewart,  E-­charting  Point-­of-­Care  Data  Entry  Dilemma,  38  J.  NURSING  ADMIN.  
417,  417  (2008).    
169  PHILLIPS  &  GONG,  supra  note  166,  at  591.  
170  Id.  
171  Saveli  I.  Goldberg  et  al.,  Analysis  of  Data  Errors  in  Clinical  Research  Databases,  2008  
AMIA  ANN.  SYMP.  PROC.  242,  244.  
172  Id.  A  second  study  by  the  same  authors  examined  weight  measurement  errors.  An  algorithm  
checked  the  weight  records  of  25,000  patients,  including  420,469  weight  entries.  It  found  errors  in  
RIHQWULHVLQWKHUHFRUGVRI³XSWRRIDOOSDWLHQWV´See  Saveli  Goldberg  et  al.,  A  Weighty  
Problem:  Identification,  Characteristics  and  Risk  Factors  for  Errors  in  EMR  Data ,  2010  AMIA  ANN.  
SYMP.  PROC.  251,  253-­54.    
173  Meredith  L.  Nahm  et  al.,  Quantifying  Data  Quality  for  Clinical  Trials  Using  Electronic  Data  
Capture,  3  PLOS  ONE  1,  1  (2008)  (discussing  a  literature  review  of  ³  articles  that  provided  source-­
to-­GDWDEDVHHUURUUDWHVSULPDULO\IURPUHJLVWULHV´DQGILQGLQJWKDWWKH³DYHUDJHHUURUUDWHDFURVVWKHVH
SXEOLFDWLRQVZDVHUURUVSHUILHOGV´See  also  Krystl  Haerian  et  al.,  Use  of  Clinical  
Alerting  to  Improve  the  Collection  of  Clinical  Research  Data ,  2009  AMIA  ANN.  SYMP.  PROC.  218,  
218  (discussing  data  error  rates  pertaining  to  research  databases).   
174  Aviv  Shachak  et  al.,  3ULPDU\&DUH3K\VLFLDQV¶8VHRf  an  Electronic  Medical  Record  System:  
A  Cognitive  Task  Analysis,  24  J.  GEN.  INTERNAL  MED.  341,  342-­44  (2009).    
175  Jennifer  R.  Pippins  et  al.,  Classifying  and  Predicting  Errors  of  Inpatient  Medication  
Reconciliation,  23  J.  GEN.  INTERNAL  MED.  1414,  1414  (2008).  
176  Id.  at  1416.    
177  Id.  
178  Id.  
179  Id.  at  1417.  




Data  errors  can  skew  the  outcomes  of  research  studies.  A  study  that  focused  on  
SQHXPRQLD FDVHV HPSKDVL]HG WKDW HYHQ D VPDOO QXPEHU RI HUURUV FDQ KDYH ³D
UHODWLYHO\ ODUJH HIIHFW´RQPRUWDOLW\ HVWLPDWHV180  Other   researchers  have   confirmed  
that   even   error   rates   as   small   as   one   to   five   percent   could   cause   significant  
inaccuracies   in   mortality   and   adverse   event   estimates.181   Database   operators   and  
analysts   also   cannot   ignore   the   possibility   that   in   the   worst-­case   scenario,   hackers  
could   access   biomedical   databases   and   intentionally   introduce   errors   or   alter  
records.182   Data   errors   that   do   not   occur   at   random   are   especially   problematic  
because  they  may  systematically  bias  research  outcomes.183  
Like   EHR   databases,   genome-­sequencing   projects   have   been   plagued   by  
genome   annotation   errors.184  One   study   found   that   the   frequency   of  misannotation  
has   grown   during   the   years   1993   to   2005   and   that   the   protein   sequence   databases  
that  were   studied   exhibited   levels   of   annotation   errors   spanning   from   zero   to   over  
sixty  percent.185  3UREOHPV UDQJH IURPSODLQ VSHOOLQJPLVWDNHV WR ³LQFRUUHFWO\ WXQHG
SDUDPHWHUV LQ DXWRPDWLF DQQRWDWLRQSLSHOLQHV´186   and   they   can   significantly   impact  
VFLHQWLVWV¶ DELOLW\ WR OHDUQ DERXW WKH HYROXWLRQ ELRORJ\ PHWDEROLF SURFHVVHV DQG
other  aspects  of  organisms.187  Experts  have  called  for  the  development  of  guidelines  
and   standards   to   improve   the   submission,   retrieval,   processing,   and   analysis   of  
genomic  data.188  
B.  INCOMPLETE  OR  FRAGMENTED  DATA  
Incomplete   or   fragmented   data   may   also   compromise   the   reliability   of   EHR  
database   information.   At   times,   EHR   data   does   not   include   all   of   the   information  
needed   for  particular   research  projects.189  Clinicians  generally  do  not   approach   the  
task   of   EHR   documentation   with   research   studies   in  mind.190   To   illustrate,   in   one  
                                                                                                  
180  George  Hripcsak  et  al.,  Bias  Associated  with  Mining  Electronic  Health  Records,  6  J.  BIOMED.  
DISCOVERY  &  COLLABORATION  48,  52  (2011).    
181  Steve  Gallivan  &  Christina  Pagel,  Modelling  of  Errors  in  Databases,  11  HEALTH  CARE  
MGMT.  SCI.  35,  39  (2008);;  Christina  Pagel  &  Steve  Gallivan,  Exploring  Potential  Consequences  on  
Mortality  Estimates  of  Errors  in  Clinical  Databases ,  20  IMA  J.  MGMT.  MATHEMATICS  385,  391  
(2009).  
182  See  Jennifer  Dobner,  Fallout  Grows  from  Hacking  of  Utah  Health  Database,  REUTERS  (Apr.  
9,  2012),  http://www.reuters.com/article/2012/04/10/us-­usa-­hackers-­utah-­idUSBRE83904G20120410  
(discussing  an  incident  in  which  Eastern  European  hackers  gained  access  to  state  health  records  of  
over  780,000  patients).  
183  Sander  Greenland,  MultipleǦBias  Modelling  for  Analysis  of  Observational  Data,  168  J.  ROYAL  
STAT.  SOC¶Y:  SERIES  A  (STAT.  IN  SOC¶Y)  267,  267-­68  (2005).  
184  Murray  P.  Cox  et  al.,  SolexaQA:  At-­A-­Glance  Quality  Assessment  of  Illumina  Second-­
Generation  Sequencing  Data,  11  BMC  BIOINFORMATICS  485,  485  (2010);;  William  Klimke  et  al.,  
Solving  the  Problem:  Genome  Annotation  Standards  Before  the  Data  Deluge ,  5  STANDARDS  IN  
GENOMIC  SCIS.  168,  168  (2011);;  Alexandra  M.  Schnoes  et  al.,  Annotation  Error  in  Public  Databases:  
Misannotation  of  Molecular  Function  in  Enzyme  Superfamilies ,  5  PLOS  COMPUTATIONAL  BIOLOGY  1,  
1  (Dec.  2009).  
185  Schnoes  et  al.,  supra  note  184,  at  2,  6.  
186  Klimke  et  al.,  supra  note  184,  at  169.  
187  Id.  at  168.  
188  Id.  at  170.  
189  Craig  D.  Newgard  et  al.,  Electronic  Versus  Manual  Data  Processing:  Evaluating  the  Use  of  
Electronic  Health  Records  in  Out-­of-­Hospital  Clinical  Research,  19  ACAD.  EMERGENCY  MED.  217,  
224  (2012).  
190  M.  Alan  Brookhart  et  al.,  Confounding  Control  in  Healthcare  Database  Research:  Challenges  
and  Potential  Approaches,  48  MED.  CARE  S114,  S115  (2010)  (explaining  that  one  of  the  limitations  of  
KHDOWKFDUHGDWDEDVHVLVWKDW³EHFDXVHWKHGDWDZHUHQRWFROOHFWHGDVSDUWRI>D@GHVLJQHGVWXG\PDQ\
variables  that  the  researcher  might  wish  to  have  access  to  UHPDLQXQUHFRUGHG´  
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instance,   a  manual   review   of   EHR   data   from   the  New  York-­Presbyterian  Hospital  
clinical   data   warehouse   revealed   that   when   pneumonia   patients   died   in   the  
HPHUJHQF\GHSDUWPHQW FOLQLFLDQV ³VSHQW OLWWOH WLPHGRFXPHQWLQJ V\PSWRPV VR WKDW
in   the   electronic   health   record,   the   patient   appeared   to   be   healthy   other   than   the  
GHDWK´191    
Data   about   treatment   outcomes   is   particularly   likely   to   be   missing.192   For  
example,  a  patient  discharged  from  an  emergency  room  may  not  seek  further  care  at  
all   or   may   later   visit   a   physician   who   has   a   different   EHR   system,   making   it  
impossible   to   track  whether   the   treatment  was   effective   over   the   long-­term.193  The  
absence  of  information  about  treatment  outcomes  in  an  EHR  is  difficult  to  interpret.  
It  could  mean  that  the  therapy  cured  the  patient,  and  she  did  not  report   the  positive  
result  because  she  required  no  follow-­up,  but  it  could  also  mean  she  experienced  no  
relief,  or  her  condition  deteriorated  and  she  went  to  a  specialist  or  another  doctor.     
Data   fragmentation   often   exists   because   different   facilities   have  EHR   systems  
that  are  not   interoperable.194  Thus,  seriously   ill  patients  who  are   treated  at  multiple  
medical   centers   as   their   disease   progresses  may   have   their   records   divided   among  
several  EHR  systems,  and   these  are  unlikely   to  be   integrated   into  a  single  research  
database.195  
C.  DATA  CODING,  STANDARDIZATION,  AND  EXTRACTION  
Medical   data   in   EHRs   is   often   coded,   but   the   coding   can   be   inconsistent,  
incorrect,   or  misleading.196   Healthcare   providers   code   data   in   accordance  with   the  
International  Classification  of  Disease,  version  9   (ICD-­9),  developed  by   the  World  
Health  Organization,   and   the  Current   Procedural  Terminology,   version   4   (CPT-­4),  
formulated   by   the   American   Medical   Association   to   record   procedures   and  
laboratory  tests.197  By  2014,  healthcare  providers  will  be  required  to  switch  to  ICD-­
10,   which   has   approximately   155,000   codes   rather   than   ICD-­¶V  FRGes.198  
                                                                                                  
191  Hripcsak  et  al.,  supra  note  180,  at  50.  It  is  especially  challenging  to  analyze  the  effects  of  
treatments  or  exposures  in  the  face  of  data  with  missing  items  if  they  are  not  missing  completely  at  
random.  Such  non-­random  omissions  create  the  potential  for  biased  results.  Craig  H.  Mallinckrodt  et  
al.,  Assessing  and  Interpreting  Treatment  Effects  in  Longitudinal  Clinical  Trials  with  Missing  Data,   
53  BIOLOGICAL  PSYCHIATRY  754,  755  (2003).  
192  Newgard  et  al.,  supra  note  189,  at  225.    
193  Id.  
194  Interoperable  systems  can  communicate  with  each  other,  exchange  data,  and  operate  
seamlessly  and  in  a  coordinated  fashion  across  organizations.  BIOMEDICAL  INFORMATICS:  COMPUTER  
APPLICATIONS  IN  HEALTH  CARE  &  BIOMEDICINE  952  (Edward  H.  Shortliffe  &  James  J.  Cimino  eds.,  
2006).    
195  Botsis  et  al.,  supra  note  40,  at  4  (stating  that  the  EHR  system  that  was  mined  for  purposes  of  
the  study  did  not  contain  records  of  patients  who  were  transferred  to  dedicated  cancer  centers  because  
of  the  severity  of  their  disease  or  who  had  initially  been  treated  elsewhere).   
196  Naren  Ramakrishnan  et  al.,  Mining  Electronic  Health  Records,  COMPUTER  95,  96  (2010),  
available  at  KWWSSHRSOHFVYWHGXUDPDNULVSDSHUVHKUPLQLQJSGIGLVFXVVLQJ³WKHODFNRIGDWD
VWDQGDUGV´  
197  Id.  at  95.  
198  HHS  Issues  Final  ICD-­10  Sets  and  Updated  Electronic  Transaction  Standards  Rules,  U.S.  
DEP¶T  OF  HEALTH  &  HUMAN  SERVS.  (Jan.  15,  2009),  
http://www.hhs.gov/news/press/2009pres/01/20090115f.html;;   ICD-­10,  CTRS.  FOR  MEDICARE  &  
MEDICAID  SERVS.,  http://www.cms.gov/Medicare/Coding/ICD10/index.html?redirect=/ICD10  (last  
modified  Sept.  9,  2013)  (indicating  that  HHS  published  a  proposed  rule  that  would  delay  the  
compliance  date,  setting  it  at  October  1,  2014  rather  than  October  1,  2013);;   ICD-­10  Code  Set  to  
Replace  ICD-­9,  AM.  MED.  ASS¶N,  http://www.ama-­assn.org/ama/pub/physician-­resources/solutions-­
managing-­your-­practice/coding-­billing-­insurance/hipaahealth-­insurance-­portability-­accountability-­
act/transaction-­code-­set-­standards/icd10-­code-­set.page  (last  visited  Oct.  22,  2010).  




EHR  systems  also  provide  their  own  selection  menus  with  various  codes  to  facilitate  
data  entry.199    
Critics   have   charged   that   healthcare   providers   often   use   coding   to   maximize  
billing  opportunities,  rather  than  to  build  the  most  accurate  record  possible.200  Menus  
and   lists   built   into   EHR   systems   may   encourage   clinicians   to   charge   for   more  
services  by  suggesting  items  for  which  they  can  bill  and  making  it  easy  to  click  on  
boxes   for   billing   purposes.201   2QH VWXG\ IRXQG WKDW WKH SUDFWLFH RI ³XSFRGLQJ´
services   provided   to  Medicare   patients   was   very   common   and  may   account   for   as  
PXFKDVILIWHHQSHUFHQWRI0HGLFDUH¶VH[SHQGLWXUHVIRUJHQHUDORIILFHYLVLWVRU
billion  annually.202  0HGLFDUHFRGLQJFRQWDLQVPDQ\DPELJXLWLHVWKDWHQDEOHGRFWRUV¶
offices   to   make   strategic   choices   that   will   enhance   their   revenues.203   The   Federal  
Government   has   recognized   the   problem   and   is   reportedly   investigating  Medicare  
fraud  related  to  upcoding.204  
Several   studies  have   specifically   identified   coding   inadequacies   as   an  obstacle  
to   secondary   use   of   EHR   data.205   According   to   one   source,   ICD-­9   codes   are   not  
specific  enough  for  cancer  to  enable  researchers  to  distinguish  primary  tumors  from  
metastatic   ones.206   ICD-­9   coding  deficiencies  will   remain   a  problem  even   after   the  
adoption  of  ICD-­10  because  existing  patient  records  will  contain  ICD-­9  codes.207  A  
British  study  examined  the  separate  codes  offered  by  a  general  practice  EHR  system  
and   concluded   that   the   coding   screen   did   not   clarify   which   designation   was  
appropriate   for   acute   rather   than  more  moderate  disease   and  which   range  of   codes  
indicate   the   presence   of   chronic   obstructive   pulmonary   disease.208   In   addition,   the  
study  found  that  different  physician  groups  use  different  codes  to  label  the  same  type  
of   patient,   so,   for   example,   some   patients   receiving   medication   to   combat  
osteoporosis  were  not  coded  as  having  osteoporosis.209  
Discrepancies  and  variability  in  quality  of  data  may  be  attributable  to  a  number  
of   factors.   According   to   one   source,   record-­keeping   was   found   to   be   more  
meticulous   if   it   was   relevant   to   financial   gain,   contractual   obligations,   or   external  
                                                                                                  
199  Simon  de  Lusignan  et  al.,  Routinely-­Collected  General  Practice  Data  Are  Complex,  but  With  
Systematic  Processing  Can  Be  Used  for  Quality  Improvement  and  Research ,  14  INFORMATICS  IN  
PRIMARY  CARE  59,  62  (2006)  DQDO\]LQJD³SLFNLQJOLVWWDNHQIURPDJHQHUDOSUDFWLFHFRPSXWHU
V\VWHP´  
200  Ramakrishnan  et  al.,  supra  note  196,  at  95;;  Peter  V.  Jensen  et  al.,  Mining  Electronic  Health  
Records:  Towards  Better  Research  Applications  and  Clinical  Care ,  13  NATURE  REVS.  GENETICS  395,  
401  (2012)  PHQWLRQLQJ³V\VWHPDWLFHUURQHRXVXVHRIGLVHDVHWHUPLQRORJ\FRGHVFDXVed  by  strategic  
ELOOLQJ´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DVVHUWLQJWKDW³WKHSULPDU\GULYHURI(+5LPSOHPHQWDWLRQKDV
EHHQFOLQLFDOUHLPEXUVHPHQWUDWKHUWKDQWKHSRWHQWLDOIRUUHXVHRIWKHFOLQLFDOGDWDIRUUHVHDUFK´   
201  OFFICE  INSPECTOR  GEN.,  U.S.  DEPT.  HEALTH  &  HUMAN  SERVS.,  TOP  MANAGEMENT  &  
PERFORMANCE  CHALLENGES  (2012),  https://oig.hhs.gov/reports-­and-­publications/top-­
challenges/2012/issue09.asp.  
202  Christopher  S.  Brunt,  CPT  Fee  Differentials  and  Visit  Upcoding  Under  Medicare  Part  B,  20  
HEALTH  ECON.  831,  840  (2011).  The  $2.13  billion  figure  is  in  2007  dollars.  Id.  
203  Id.  
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viewers,  and  more  sloppy  if  it  was  used  internally  only.210  In  addition,  the  existence  
of   multiple   fields   for   documentation   and   variable   practices   among   different  
personnel   (e.g.,  documenting   scheduled  date  versus   actual   date  of   an   appointment)  
can   generate   irregularities.211   <HW DQRWKHU FRPSOLFDWLRQ LV PHGLFDO RIILFHV¶
inconsistent  use  of  terms,  phrases,  and  abbreviations.  To  illustrate,   the  abbreviation  
³06´ FDQ PHDQ ³PLWUDO VWHQRVLV´ ³PXOWLSOH VFOHURVLV´ ³PRUSKLQH VXOIDWH´ RU
³PDJQHVLXPVXOIDWH´212  If  the  context  is  not  clear  from  the  EHR,  a  reader  might  fail  
WRXQGHUVWDQGZKDWLVPHDQWE\³06´LQDSDUWLFXODUUHFRUG   
Further  challenges  arise  from  the  existence  of  free  text  narrative  in  EHRs.  EHR  
systems  allow  providers   to  enter  both  coded   information  and  unstructured,  natural-­
language   notes   about   patients.213   Important   information   that   is   not   captured   in  
structured   data   may   be   contained   in   notes,   and   such   information   is   much   more  
difficult   to   extract   accurately   from   EHRs   for   secondary   use.214   As   an   example,  
database  mining  may  fail  to  reveal  a  link  between  worsening  asthma  and  smoking  if  
the  progression  of  asthma  is  coded  but  smoking  history  is  described  only  in  free-­text  
clinical  notes.215  Similarly,  family  history  and  information  about  adverse  reactions  to  
drugs   are   likely   to   be   presented   in   narrative   form   rather   than   in   coded   form.216  
Experts  may  employ  natural-­language  processing  tools  to  extract  data  from  free-­text  
narrative,  but  these  techniques  are  still  developing  and  are  often  imperfect. 217  
If   diagnoses,   measurements,   or   medical   histories   contained   in   EHRs   are   not  
standardized   or   are   inaccessible   because   they   do   not   appear   in   structured   form,  
database   contents   may   be   inadequate   for   secondary   uses.218   Similarly,   if   medical  
vocabulary  is  not  harmonized,  researchers  may  misunderstand  or  be  unable  to  make  
sense  out  of  database  records.  
D.  ERRORS  DUE  TO  SOFTWARE  FAILURES  
Errors   in   research   data   and   in   the   results   of   computer   analysis   can   also   result  
from   incorrect   processing   by   defective   software.   EHR   systems,   like   any   complex  
software  system,  may  contain  unrecognized  or  unrepaired  software  defects.219  Such  
GHIHFWVPD\FDXVHVRPHRI WKHGDWDUHFRUGHG LQDSDWLHQW¶V(+5WREH LQFRUUHFW$
value  that  is  incorrect  but  is  nevertheless  plausible  may  not  be  discovered  and  hence  
may  remain  in  DSDWLHQW¶V(+5ZKHQLWLVXVHGLQDUHVHDUFKVWXG\  
Even   if   the   raw   data   is   correct,   errors   may   arise   during   data   analysis   due   to  
defects   in   the  software  used   to  conduct   the  analysis.220  This   is  particularly   likely   if  
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KNOWLEDGE  MANAGEMENT  &  DATA  MINING  IN  BIOMEDICINE  163,  170  tbl.  6-­1  (Hsinchun  Chen  et  al.  
eds.,  2010).  
213  S.  Trent  Rosenbloom  et  al.,  Data  from  Clinical  Notes:  A  Perspective  on  the  Tension  Between  
Structure  and  Flexible  Documentation,  18  J.  AM.  MED.  INFORMATICS  ASS¶N  181,  181-­82  (2011).  
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(2011).  
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the  software  is  complex  and  is  developed  by  scientists  or  their  assistants  without  the  
help  of  skilled  software  developers.221  Inexperienced  programmers  are  likely  both  to  
create  incorrect  software  and  to  test  it  inadequately.222  Even  commercially  developed  
biomedical   research   software,   however,   may   produce   erroneous   results.223   Ideally,  
scientists   should   work   in   close   cooperation   with   software   experts   to   develop   and  
thoroughly  validate  software  used  in  biomedical  research.    
IV.THE  CHALLENGES  OF  BIAS  AND  CAUSAL  INFERENCE  
As  argued  above,  the  availability  of  large  collections  of  data  does  not  guarantee  
sound   study  outcomes.224  Even   if   the  data   itself   is   unblemished,   those   analyzing   it  
will  face  many  obstacles  to  drawing  correct  conclusions  from  it.  This  Part  analyzes  
subtle  but   important  problems  of  bias  affecting  observational   studies,   in  particular,  
selection  bias,  confounding  bias,  and  measurement  bias.  An  understanding  of   these  
issues   is   crucial   for   anyone   seeking   to   interpret   the   results   of   biomedical   database  
studies.    
It  is  worth  noting  that  one  type  of  problem,  namely  sampling  error,  is  less  likely  
to  be  a  major  concern  in  observational  studies  based  on  large  biomedical  databases.  
Sampling   error   arises  when   inferences   are  drawn   from  observations  of   a   randomly  
chosen   sample   of   individuals   whose   statistical   characteristics   (e.g.,   smoking   rate,  
average   weight,   or   average   duration   of   illness)   differ   from   those   of   the   source  
population  due  to  random  chance.225  Conclusions  drawn  from  the  particular  sample,  
therefore,   cannot   be   accurately   generalized   to   the   population   of   interest.   Sampling  
error   tends   to  diminish   as   the   sample   size   increases,   and   the   extent   of   this   error   is  
well   characterized   by   traditional   statistical   methods   such   as   computation   of  
confidence  intervals.226  Since  the  research  databases  contemplated  in  this  Article  are  
large   and   automatically  queried,   considerable   samples   can  be  processed   efficiently  
to   reduce   sampling   error.   However,   selection   bias   can   nevertheless   result   if   the  
individuals  whose   records   are   stored   in   a  biomedical   database   and  who   satisfy   the  
criteria   for   a   given   study   do   not   constitute   a   random   sample   of   the   population  
targeted  by  the  study.  
A.  SELECTION  BIAS    
If  data  subjects  have   the  opportunity   to  opt  out  of   inclusion   in  a  database  or   if  
FHUWDLQLQGLYLGXDOV¶UHFRUGVDUHRWKHUwise  excluded,  a  class  of  problems  often  called  
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³VHOHFWLRQ ELDV´ PD\ DULVH227   Selection   bias   may   occur   when   the   subset   of  
individuals  studied  is  not  representative  of  the  patient  population  of  interest. 228  This  
kind  of  selection  bias  could  manifest,   for  example,   if  a  disproportionate  number  of  
people  of  one  ancestry  or  economic  class  opt  out  of  participating  in  a  database.229  It  
can  likewise  exist  if  individuals  with  certain  behavior  traits  that  might  be  important  
in   some   studies²such   as   diet,   exercise,   smoking   status,   and   alcohol   or   drug  
consumption²choose  not  to  participate  or  cannot  access  medical  facilities  in  which  
studies   take   place.230   Selection   bias   can   distort   assessments   of   measures   such   as  
disease   prevalence   or   exposure   risk   because   study   estimates   will   differ  
systematically   from   the   true   values   of   these   measures   for   the   target   population.231  
That   is,   the   estimates   will   not   be   generalizable   from   the   research   subjects   to   the  
larger  population  about  which  analysts  wish  to  draw  conclusions.232    
Another,   more   VXEWOH NLQG RI VHOHFWLRQ ELDV ZKLFK LV DOVR FDOOHG ³FROOLGHU-­
VWUDWLILFDWLRQ ELDV´233   ³FROOLGHU-­ELDV´234   RU ³0-­ELDV´235   is   specific   to   causal-­effect  
studies.   236  These  studies   typically  seek   to  measure   the  average  beneficial  effect  on  
patients   of   a  particular   treatment  or   the   average  harmful   effect   on   individuals  of   a  
particular   exposure.237   Collider-­stratification   bias   occurs   in   analyzing   study   data  
when   the   analysis   is   conditioned   on   (e.g.,   stratified   by)   one   or   more   levels   of   a  
variable   that   is   a   common   effect   D ³FROOLGHU´ RI ERWK WKH WUHDWPHQWH[SRVXUH
variable   and   the   outcome   variable   or   that   is   a   common   effect   of   a   cause   of   the  
treatment/exposure  and  a  cause  of  the  outcome.238    
Consider   the   following   classic   example.   Commonly,   some   patients   are   lost   to  
follow-­up,   and   thus   outcome   measurements   that   would   be   essential   for   research  
purposes  are  unavailable.  The  data  from  these  patients  cannot  be  included  in  studies.  
Both  the  treatment  and  outcome  at  issue  may  influence  which  patients  stop  seeking  
medical  care.  Patients  may  fail  to  return  for  follow-­up  both  because  the  treatment  is  
XQSOHDVDQW WUHDWPHQW IDFWRU DQG EHFDXVH WKH\ DFWXDOO\ IHHO EHWWHU DQG GRQ¶W VHH D
need  to  return  to  their  doctors  (an  outcome  factor).  The  loss  of  these  study  subjects  
can  create  a  spurious  statistical  association  between  the  treatment/exposure  variable  
and  the  outcome  variable  that  becomes  mixed  with  and  distorts  the  true  causal  effect  
of   the   former  on   the   latter.239  Because  collider-­stratification  bias   is  associated  with  
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the  exclusion  of  some  patients  from  a  study,  it   is  categorized  as  a  type  of  selection  
bias.240    
B.  CONFOUNDING  BIAS  
In  observational   causal-­effect   studies,   confounding  bias   (confounding)  may  be  
an   even   greater   concern   than   selection   bias.241   ³&ODVVLFDO´ FRQIRXQGLQJ RFFXUV
because  of   the  presence  of  a  common  cause  of   the   treatment/exposure  variable  and  
the   outcome   variable.242   Confounding   is   different   from   collider-­stratification   bias  
because   it   involves   a   common   cause   of   the   treatment/exposure   and   outcome  
variables  rather  than  a  common  effect  of  the  variables.243    
The   following   hypothetical   illustrates   classical   confounding.   Suppose   a  
SK\VLFLDQ¶VWUHDWPHQWFKRLFHVDUHLQIOXHQFHGE\WKHVHYHULW\RUGXUDWLRQRIDSDWLHQW¶V
disease,  which   also   influence   the  outcome  of   treatment.244   Thus,   patients   at   a   later  
stage  of  a  disease  may  receive  one  treatment  (treatment  A)  and  those  who  are  at  an  
earlier  stage  may  receive  a  different  therapy  (treatment  B).  At  the  same  time,  sicker  
patients  may  have  worse  treatment  outcomes  than  healthier  individuals.  Unless  such  
D FRPPRQ FDXVH ZKLFK LV FDOOHG D ³FRQIRXQGLQJ YDULDEOH´ RU ³FRQIRXQGHU´ LV
adjusted   for   appropriately  during   statistical   data   analysis,   it  may   induce   a   spurious  
association  between  the  treatment  variable  and  the  outcome  variable,  which  distorts  
estimation  of  the  true  causal  effects  of  treatments.245  In  other  words,  researchers  may  
reach   incorrect  conclusions  regarding   the  efficacy  of   the   two  treatments  because  of  
the   confounding   variable:   the  degree  of   sickness   suffered  by  patients   receiving   the  
different  therapies.  Treatment  A  may  appear  to  be  less  effective  than  treatment  B  not  
because  it  is  in  fact  an  inferior  therapy  but  because  so  many  of  the  patients  receiving  
treatment  A  are  in  a  late  stage  of  the  disease  and  would  not  do  well  no  matter  what  
WUHDWPHQW WKH\ UHFHLYHG7KLV SDUWLFXODU IRUPRI FRQIRXQGLQJ FDOOHG ³FRQIRXQGLQJ
E\ LQGLFDWLRQ´ LV HVSHFLDOO\ FKDOOHQJLQJ WR DGMXVW IRU EHFDXVH LW PD\ LQYROYH
PXOWLSOHIDFWRUVWKDWLQIOXHQFHSK\VLFLDQV¶WUHDWPHQWGHFLVLRQV246  
Socioeconomic   factors   and   patient   lifestyle   choices   may   also   be   confounders.  
Those   who   lack   financial   resources   or   adequate   health   coverage   may   select   less  
expensive   treatments   not   because   those   are   the   best   choices   for   them   but   because  
those   are   the   only   affordable   options.247   Low   income   may   also   separately   lead   to  
poor   health   for   reasons   such   as   poor   nutrition   or   financial   stress.    In   the   case   of  
SUHYHQWLYHFDUHD WUHDWPHQW¶VSHUFHLYHGEHQHILWVPD\EH DPSOLILHGEHFDXVHKHDOWK-­
oriented  individuals  interested  in  the  intervention  also  pursue  exercise,  low-­fat  diets,  
and   other   health-­SURPRWLQJ EHKDYLRUV 7KHVH SDWLHQWV¶ LPSUHVVLYH RXWFRPHV WKXV
would  not  be  associated  solely  with  the  preventive  measure.248  
                                                                                                  
240  Collider-­stratification  bias  may  also  occur  because  of  a  poorly  conceived  attempt  to  adjust  for  
confounding  bias,  discussed  below.  Hernán  et  al.,  supra  QRWHDWVWDWLQJWKDW³>D@OWKRXJK
stratification  is  commonly  used  to  adjust  for  confounding,  it  can  have  unintended  effects´  
241  See  Sander  Greenland,  Quantifying  Biases  in  Causal  Models:  Classical  Confounding  vs.  
Collider-­Stratification  Bias,  14  EPIDEMIOLOGY  300,  306  (2003).  
242  See  id.  at  301.  
243  Hernán  et  al.,  supra  note  231,  at  615.    
244  See  Bruce  M.  Psaty  &  David  S.  Siscovick,  Minimizing  Bias  Due  to  Confounding  by  Indication  
in  Comparative  Effectiveness  Research,  304  J.  AM.  MED.  ASS¶N  897,  897  (2010).  
245  Hernán  et  al.,  supra  note  231,  at  618.  
246  See  Jaclyn  L.F.  Bosco  et  al.,  A  Most  Stubborn  Bias:  No  Adjustment  Method  Fully  Resolves  
Confounding  by  Indication  in  Observational  Studies ,  63  J.  CLINICAL  EPIDEMIOLOGY  64,  70  (2010).  
247  See  Brookhart  et  al.,  supra  note  190,  at  S115.  
248  Id.  
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To   reduce   or   eliminate   confounding   bias   in   an   observational   study,   those  
conducting  it  must  strive  to  ascertain,  accurately  measure,  and  adjust  for  all  potential  
confounding   variables.249   In  many   studies,   however,   it   is   by   no  means   clear  which  
variables   are  potential   confounders.  Medical   care   is   often  dependent  on   a   complex  
web   of   variables   relating   to   the   healthcare   system,   clinicians,   and   patients  
themselves,  and  the  factors  at  work  in  each  case  may  not  be  obvious.250    
Ideal   randomized   experiments,   when   they   are   feasible,   prevent   confounding  
because   randomly   assigning   treatments   to   patients   (possibly   including   a   placebo)  
ensures   there   are   no   associations   between   the   treatment   variable   and   potential  
confounding   variables.251   In   an   observational   study,   investigators   do   not   control  
treatment   assignment  because   they   review   records   that   reflect   treatments   that   have  
been   previously   administered.252   Researchers   must   therefore   attempt   to   obtain   the  
values   of   confounding   variables   and   adjust   for   them   during   analysis   of   the   study  
data.253    
One   option   is   to   restrict   the   values   of   the   confounding   variables²that   is,   to  
exclude  subjects  for  whom  the  values  of  these  variables  are  outside  a  chosen  range²
in  order  to  ensure  that  the  treatment  groups  are  similar  to  each  other.254  For  example,  
in   an   observational   study   of   the   comparative   effectiveness   of   diuretics   and   beta  
blockers  for  the  prevention  of  heart  attacks,  researchers  could  minimize  confounding  
by  indication  by  restricting  the  analysis  to  patients  without  any  evidence  of  clinical  
cardiovascular   disease.255  This   restriction   is   desirable  because   among  patients  with  
cardiovascular  disease,   the  use  of  beta  blockers  rather   than  diuretics   is  an   indicator  
of  more  severe  disease  and  greater  pre-­treatment  risk  of  heart  attack.256  Pre-­existing  
disease  in  those  taking  beta  blockers  could  skew  study  results  and  make  it  difficult  to  
ascertain   the   relative   effectiveness   of   the   two   drugs.   The   disadvantage   of   this  
restriction   is   that   the   results   obtained   do   not   generalize   directly   to   the   entire  
population  of  patients   taking  diuretics  or  beta  blockers,  because  many   in   fact   have  
cardiovascular  disease.257  
In  some  studies  in  which  restriction  is  necessary,  it  is  possible  to  generalize  the  
results   based   on   existing   knowledge.258   For   example,   although   the   causal   link  
between  smoking  and  lung  cancer  was  established  mainly  through  studies  with  male  
subjects,  experts  assumed  the  association  existed  in  women  too,  because  the  lungs  of  
men  and  women  are  anatomically  similar.259  In  other  cases,  confounding  bias  can  be  
controlled,   without   eliminating   any   groups   of   subjects   from   the   analysis,   by  
computing  separate  causal-­effect  estimates  for  each  stratum  (level)  of  a  confounding  
variable.260  Thus,  if  age  is  a  confounder,  analysts  could  calculate  separate  estimates  
for  each  ten-­year  interval  of  patient  ages  (birth  to  ten  years  old,  ten  to  twenty  years  
old,   etc.).   If   the   study   cohort   is   representative  of   the   target   population,   researchers  
can  obtain  an  estimate  of  the  average  causal  effect  in  the  population  by  computing  a  
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weighted  average  of  the  stratum-­specific  effect  estimates,  where  the  weight  for  each  
VWUDWXPLVWKHUDWLRRILWVVL]HWRWKHHQWLUHFRKRUW¶VVL]H261    
C.  MEASUREMENT  BIAS  
Measurement   biases   arise   from   errors   in   measurement   and   data   collection.262  
Observational  study  results  may  be  compromised   if   the  biomedical   records   that  are  
analyzed   contain   such   errors.   Measurement   errors   occur   for   a   variety   of   reasons.  
Measurement   instruments  might  not  be  calibrated  properly  or  might   lack  sufficient  
sensitivity   to   detect   differences   in   relevant   variables.263   Storage   time   or   conditions  
for   biological   samples  might   be   different   and  might   affect   study   results.264   To   the  
H[WHQW WKDW UHVHDUFKHUVVROLFLWDQGUHFRUGSDWLHQWV¶RZQDFFRXQWVDQGPHPRULHV WKH
VXEMHFWV¶DELOLW\WRUHFDOOGHWDLOVPD\EHLQIOXHQFHGE\WKHTXHVWLRQHU¶VFRPSHWHQFH
patience,  and  apparent  sympathy  or  by  the  degree  to  which  the  patient  perceives  the  
topic   to   be   important   and   relevant   to   her   life.265   In   addition,   patients   may   have  
impaired  memories  or  may  lie  in  response  to  questions  if  they  are  embarrassed  about  
the   truth.266   Accurate   measurement   may   be   further   hindered   by   incomplete,  
erroneous,  or  miscoded  EHR  data  that  obfuscates  true  values.267  
In  causal-­effect  studies,  errors  in  measurement  of  the  treatment/exposure  and  the  
outcome  are  most  problematic  when  they  are  associated  (dependent)  and  when  they  
are   differential,   that   is,   when   the   treatment   affects   the   measurement   error   for   the  
outcome   or   the   outcome   affects   the   measurement   error   for   the   treatment. 268   For  
example,   differential   measurement   error   could   occur   in   a   study   of   the   effect   of  
treatment  A  on  dementia,  if  the  use  of  A  was  determined  only  by  interviewing  study  
SDUWLFLSDQWV EHFDXVH GHPHQWLD DIIHFWV VXEMHFWV¶ DELOLW\ WR UHFDOO ZKHWKHU DQG KRZ
they   were   treated.269   Mismeasurement   of   confounding   variables   also   impedes  
adjustments  intended  to  eliminate  confounding  bias.270  
V.  BIOMEDICAL  DATABASES  AND  PERSONAL  AGENDAS  
Individuals   with   political,   social,   or   economic   agendas   may   exploit  
observational   research  outcomes   to   influence  public   opinion   and   legislative   action.  
Manufacturers,   for  example,  may   fund  studies   regarding   their  products   in   the  hope  
of   generating   new   discoveries   concerning   the   benefits   of   those   products,   thereby  
increasing   their   sales,271   though  subsequent  marketing  efforts  would  be  constrained  
by   advertising   regulations   enforced   by   federal   agencies   such   as   the   FDA   and   the  
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Federal  Trade  Commission.272  Data  mining   of   biomedical   databases  may   facilitate  
the   discovery   of   statistical   associations   between   use   of   certain   products   and   the  
occurrence  of  desirable  outcomes  (e.g.,   lower  disease  risk).  It   is  easy  for  marketers  
to  imply  that  statistical  associations  are  causal  ones,  even  when  the  evidence  for  this  
is  dubious  because  of  confounding  or  other  biases.273  
Those   who   are   politically   motivated   may   attempt   to   use   data   that   appears  
scientific   in   order   to   pursue   legislative   or   regulatory   goals.   This   has   already  
happened.  As  noted  in  the  Introduction,  a  now-­debunked  study  finding  that  abortions  
caused  lasting  psychological  harm  to  women274  was  used  by  advocates  to  influence  
state   legislatures.   Consequently,   several   states   enacted   legislation   that   required  
clinicians   to   warn   individuals   who   seek   abortions   that   they   could   suffer   future  
mental  health  ailments.275  
Needless   to   say,   even   highly   trained   researchers   at   academic   institutions   can  
produce   low-­quality   work.   The   pressure   to   publish   for   tenure   and   promotion  
purposes  or  a  desire  for  fame  may  tempt  some  faculty  members  to  focus  excessively  
on  how  publishable  their  work  will  be,  at  the  expense  of  its  scientific  value.  At  least  
one   study   has   explored   whether   publication   pressures   themselves   generate   biases  
among  researchers  and  concluded  that  the  answer  is  yes.276  A  review  of  1316  papers  
found   that   United   States   researchers   in   competitive   academic   environments   were  
ELDVHG DJDLQVW ³QHJDWLYH´ UHVXOWV WKDW IDLOHG WR VXSSRUW WKH K\SRWKHVLV WKDW ZDV
tested.277  5HVHDUFKHUVEHOLHYHWKDW³SRVLWLYH´UHVXOWVFRQILUPLQJK\SRWKHVHVDUHPRUH
likely  to  be  published  and  subsequently  cited.278  This  assumption  may  influence  not  
only  their  choices  as  to  which  projects  to  pursue  and  which  results  to  write  up,  but  
also,  potentially,  their  objectivity  in  conducting  research.279  
The  dangers  of  misinterpretation,  deliberate  data  distortion,  flawed  studies,  and  
irresponsible   use   of   research   outcomes,   might   be   acute   if   biomedical   databases  
become   publicly   available.   Individuals  who   have   little   research   training   but   strong  
political   voices   and   easy   access   to   the   media   could   deliberately   misuse   such  
databases.    
As   argued   throughout   this   Article,   amateurs   are   unlikely   to   produce   reliable  
research   outcomes.280   Even   leading   scientists   at   times   have   difficulty   interpreting  
research   results   and   may   disseminate   confusing   or   misleading   information   to   the  
public.   A   well-­known   example   relates   to   the   effect   of   postmenopausal   hormone  
replacement  therapy  (HRT)  on  heart  disease  and  breast  cancer.281  For  several  years,  
experts   believed   that   the   outcomes   of   randomized   clinical   trials   conflicted   with  
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results  of  observational  studies  concerning  HRT.282  It  was  only  with  reanalysis  of  the  
data   that   the   two  were   reconciled.  Experts   realized   that   the  effect  of  HRT  changed  
over   time,   which   explained   the   apparent   discrepancies.283   In   the   end,   scientists  
concluded   that  HRT   increased   the   risk  of  both  heart  disease   and  breast  cancer,  but  
the  cardiovascular  risk  was  slightly  higher  for  older  women  and  the  cancer  risk  was  
higher  for  women  closer  to  menopause.284  
Yet,  regardless  of  the  quality  of  the  work  product,  anyone  can  set  up  a  website  
or   blog   and   post   documents   that   appear   to  be   serious   scientific   studies.  Moreover,  
these  can  quickly  enjoy  worldwide  dissemination.  
In  addition,  web-­savvy  people  may  employ  strategies  to  increase  the  visibility  of  
their   messages.   Even   Google   searches   are   vulnerable   to   manipulation   through  
SUDFWLFHV NQRZQ DV ³VHDUFK HQJLQH RSWLPL]DWLRQ´285  *RRJOH¶V DOJRULWKP LQFOXGHV D
SRSXODULW\PHWULFFDOOHG3DJH5DQNZKLFKFRQVLGHUV³LQERXQG OLQNV WRDZHEVLWHDV
SRSXODULW\ YRWHV´286   Website   owners   can   increase   traffic   to   their   sites   by   paying  
other   websites   to   link   to   them.287   They   can   also   try   to   trick   the   search   engine   by  
showing   Google   crawlers288   information   that   is   different   from   that   available   to  
users.289  Yet,  many  viewers  will  likely  assume  that  studies  that  appear  first  or  often  
in  search-­engine  results  are  necessarily  more  credible  and  valuable  than  others.  
VI.  SOLUTIONS  
We  do   not  mean   to   suggest   that   biomedical   databases   are   too   flawed   to   be  of  
value  or  that  observational  studies  based  on  such  databases  are  a  lost  cause.  Quite  to  
the   contrary,   we   are   optimistic   about   these   emerging   resources   and   capabilities.290  
The  success  of  research  initiatives,  however,  will  depend  on  advances  in  technology  
as  well  as  on  human  efforts  to  validate  biomedical  data  and  master  the  complexities  
of   conducting   sound   observational   studies.   Anyone   relying   on   record-­based   study  
outcomes,   including   government   officials,   attorneys,   and   the   public   at   large,  must  
NQRZ ZKDW TXHVWLRQV WR DVN DQG QRW EH QDwYH DERXW WKH VWXGLHV¶ YDOLGLW\ ,Q WKLV
section   we   propose   technological   enhancements,   study-­design   and   validation  
improvements,  and  educational  initiatives  to  combat  potential  database  and  research  
inadequacies  or  abuses.    
A.  TECHNOLOGY  IMPROVEMENTS    
As   EHR   system   technology   matures,   its   capacity   to   capture   accurate   and  
comprehensive  data  sets  should  continue  to  improve.  Health  information  technology  
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&  TECH.  188,  193  (2006).  
287  Facts  about  Google  and  Competition,  GOOGLE,  
http://www.google.com/competition/howgooglesearchworks.html  (last  visited  Oct.  22,  2013).     
288  *RRJOHFRQWLQXDOO\DFTXLUHVQHZLQIRUPDWLRQE\VHQGLQJ³DXWRPDWHGµVSLGHUV¶DQGµFUDZOHUV¶
RQWRWKH:HE´0RIIDWsupra  note  285,  at  481.  
289  Goldman,  supra  note  286,  at  193.  
290  See  Hoffman  &  Podgurski,  supra  note  8,  at  97-­102  (discussing  the  benefits  of  EHR-­based  
research).  
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experts   are   increasingly   likely   to   recognize   that   these   systems   serve   not   only   as  
clinical  and  billing  tools,  but  also  as  data  sources  for  secondary  use  purposes.  
Incompatibility   of   different   EHR   systems   poses   significant   challenges   for  
researchers.291  Reconciling  the  format  and  meaning  of  data  that  come  from  different  
systems   constitutes   very   resource-­intensive   and   burdensome   work   for   analysts.292  
Even  the  records  of  individual  patients  who  see  doctors  at  more  than  one  facility  can  
become  fragmented,  and  it  may  be  nearly  impossible  to  put  the  pieces  together  into  a  
cohesive  whole  if  the  separate  EHR  systems  are  not  interoperable.293  The  problem  of  
data   fragmentation   could   be   cured   through   semantic   interoperability,   which  would  
HQDEOH ³LQIRUPDWLRQ V\VWHPV WR H[FKDQJH LQIRUPDWLRQ RQ WKH EDVLV RI VKDUHG SUH-­
HVWDEOLVKHG DQG QHJRWLDWHG PHDQLQJV RI WHUPV DQG H[SUHVVLRQV´294   Health  
information  exchange  capabilities  are  essential  to  the  research  endeavor.295    
Many   barriers   hinder   the   achievement   of   semantic   interoperability.296   Among  
them  are:  (1)  the  extremely  large  number  of  stakeholders  in  the  United  States;;  (2)  the  
lack  of  coordination,  standardization,  trained  personnel,  and  appropriate  technology;;  
and  (3)  the  government  pressure  to  transition  from  paper  records  to  EHR  systems  as  
quickly  as  possible.297  In  addition,  semantic  interoperability  likely  does  not  appeal  to  
EHR   vendors.   If   vendors   standardize   their   products,   they   will   make   it   easier   for  
custoPHUVZKRKDYHRQHYHQGRU¶VSURGXFWWRVZLWFKWRDFRPSHWLWRU¶V(+5V\VWHP
Customers  could  learn  to  use  new  systems  more  easily  and  transfer  existing  records  
to  new  EHR  systems  with   less  difficulty.298  As  of  2012,  a  workgroup  consisting  of  
ten  states  and  twenty-­six  vendors  is  collaborating  to  develop  standard  specifications  
to  promote  interoperability  and  the  exchange  of  health  information,  but  progress  has  
been  slow.299    
All   stakeholders   must   continue   to   work   together   to   develop   mechanisms   to  
standardize   representations   of   EHR   information   in   order   to   eliminate   data  
                                                                                                  
291  Dipak  Kalra  et  al.,  ARGOS  Policy  Brief  on  Semantic  Interoperability,  170  STUD.  IN  HEALTH  
TECH.  &  INFORMATICS  1,  5  (2011);;  See  also  supra  Parts  III.B.-­III.C.  
292  Carole  Goble  &  Robert  Stevens,  State  of  the  Nation  in  Data  Integration  for  Bioinformatics,  41  
J.  BIOMED.  INFORMATICS  687,  687  (2008)  (statLQJWKDW³WKHLQWHJUDWLRQRIUHVRXUFHV²a  prerequisite  for  
most  bioinformatics  analysis²LVDSHUHQQLDODQGFRVWO\FKDOOHQJH´  
293  See  supra  notes  191-­192  and  accompanying  text.  
294  Kim  H.  Veltman,  Syntactic  and  Semantic  Interoperability:  New  Approaches  to  Knowledge  
and  the  Semantic  Web,  7  NEW  REV.  INFO.  NETWORKING  159,  167  (2001).  See  also  Robert  H.  Dolin  &  
Liora  Alschuler,  Approaching  Semantic  Interoperability  in  Health  Level  Seven ,  18  J.  AM.  MED.  
INFORMATICS  ASS¶N  99,  99-­100  (2010)  (providing  alternative  defiQLWLRQVRI³VHPDQWLF
interoperability´  
295  See  Botsis  et  al.,  supra  QRWHDWVWDWLQJWKDWLQFRPSOHWHQHVV³FRXOGEHPLWLJDWHGXVLQJ
KHDOWKLQIRUPDWLRQH[FKDQJH+,(PHWKRGV´+HUZHKHHWDOsupra  note  141,  at  448  (explaining  that  
³>H@OHFWURQLFKHDOth  information  exchange  (HIE)  offers  a  provider-­acceptable  means  of  utilizing  
LQIRUPDWLRQIURPPXOWLSOHVRXUFHV´-HQVHQHWDOsupra  QRWHDWVWDWLQJWKDW³(+5GDWD
need  to  be  merged  across  regional  barriers  in  order  to  provide  the  strongest  EDVLVIRUUHVHDUFK´  
296  Werner  Ceusters  &  Barry  Smith,  Semantic  Interoperability  in  Healthcare  State  of  the  Art  in  
the  US,  ST.  U.N.Y.  BUFFALO  1,  4  (2010),  
http://ontology.buffalo.edu/medo/Semantic_Interoperability.pdf.     
297  Id.  
298  M.  Alexander  Otto,  Despite  Small  Steps,  EHR  Interoperability  Remains  Elusive,  INTERNAL  
MED.  NEWS  (Jan.  31,  2011),  http://www.internalmedicinenews.com/news/more-­top-­news/single-­
view/despite-­small-­steps-­ehr-­interoperability-­remains-­elusive/71b93edeb0.html.    
299  Mike  Miliard,  EHR/HIE  Interoperability  Workgroup  Agrees  on  Connectivity  Specs,  
HEALTHCARE  IT  NEWS  (Nov.  9,  2011),  http://www.healthcareitnews.com/news/ehrhie-­
interoperability-­workgroup-­agrees-­connectivity-­specs;;  Official  PR:  10  States  Now  Unified  to  
Standardize  Health  Data  Interoperability,  EHR/HIE  INTEROPERABILITY  WORKGROUP  (Feb.  20,  2012),  
http://interopwg.org/news/OFFICIAL-­PR-­10-­States-­Now-­Unified-­to-­Standardize-­Health-­Data-­
Interoperability.html.    




ambiguities   and   facilitate   integration   of   records   from   EHR   systems   produced   by  
different  vendors.300  The  Federal  Government  could  incentivize  the  development  of  
semantic   interoperability   by   incorporating   increasingly   stringent   interoperability  
requirements   into   the   meaningful   use   regulations.301   These   regulations,   which   are  
being   implemented   in   three   stages   over   several   years,   detail   the   requirements   that  
healthcare  providers  must  meet  in  order  to  receive  federal  funding  to  assist  them  in  
implementing  EHR  systems.302  
Even   with   interoperability,  many   EHRs   would   continue   to   be   incomplete   and  
contain   inaccuracies.303   These   deficiencies   could   be   mitigated   in   part   through  
increased  use  of  electronic  means  for  collecting  patient  data,  such  as  remote  patient  
monitoring.304  A  variety  of  devices,  including  glucometers,  implantable  cardioverter-­
defibrillators,   and   blood   pressure   monitors,   can   register   clinical   measurements   at  
KRPHDQGUHSRUWWKHPWRSDWLHQWV¶KHDOWKFDUHSUoviders.305    
Several   other   technological   improvements   would   be   useful   as   well.   Enhanced  
user   interface   design   could  make   it   easier   for   clinicians   to   navigate   EHR   systems  
and   accurately   record   data.306   Voice   recognition   software,   when   sufficiently  
advanced,   could   also   reduce   the   risk   of   input   errors   and   allow   users   to   operate  
systems   more   quickly   and   to   add   additional   detail   to   their   documentation.307   As  
discussed   above,   improved   and  widely   available   natural-­language   processing   tools  
would  also  enable  analysts  to  extract  more  comprehensive  data  from  EHRs.308    
In   some  circumstances,   clinical   alerts   could   contribute   to   the   accuracy  of  data  
collection.309  If  expected  measurements  can  be  determined  in  advance,  EHRs  could  
generate   alerts   when   clinicians   enter   values   that   deviate   significantly   from   the  
anticipated   figures.310   In   one   study   focusing   on   height   and   weight   measures,  
researchers  had  an  alert  pop  up  when  clinicians  entered  figures  with  a  ten  percent  or  
                                                                                                  
300  See  Sharona  Hoffman  &  Andy  Podgurski,  Finding  A  Cure:  The  Case  for  Regulation  and  
Oversight  of  Electronic  Health  Record  Systems,  22  HARV.  J.L.  &  TECH.  103,  152-­53  (2008)  
(recommending  the  development  of  a  common  exchange  representation).   
301  See  45  C.F.R.  §§  170.205,  170.207  (2012)  (providing  current  health  information  exchange  
standards).  
302  See  EHR  Incentive  Program,  CTRS.  FOR  MEDICARE  &  MEDICAID  SERVS.,  
https://www.cms.gov/Regulations-­and-­
Guidance/Legislation/EHRIncentivePrograms/index.html?redirect=/EHRIncentivePrograms/30_Meani
ngful_Use.asp  (last  modified  June  26,  2013).    
303  See  supra  Part  III.  
304  Kevin  D.  Blanchet,  Remote  Patient  Monitoring,  14  TELEMED.  &  E-­HEALTH  127,  128-­30  
(2008);;  Technologies  for  Remote  Patient  Monitoring  in  Older  Adults,  CTR.  FOR  TECH.  &  AGING  1,  4  
(2009),  http://www.techandaging.org/RPMpositionpaperDraft.pdf.   
305  Technologies  for  Remote  Patient  Monitoring ,  supra  note  304,  at  4.  
306  See  Michael  E.  Wiklund,  Making  Medical  Device  Interfaces  More  User-­Friendly,  in  
DESIGNING  USABILITY  INTO  MEDICAL  PRODUCTS  151±60  (Michael  E.  Wiklund  &  Stephen  B.  Wilcox  
eds.,  2005)  (discussing  user-­interface  problems  and  techniques  for  enhancing  the  user-­friendliness  of  
medical  device  interfaces);;  Adrian  Williams,  Design  for  Better  Data:  How  Software  and  Users  
Interact  Onscreen  Matters  to  Data  Quality,  77  J.  AM.  HEALTH  INFO.  MGMT.  INST.  56,  56  (2006)  
VWDWLQJWKDW³>S@RRUO\GHVLJQHGVRIWZDUHWKDWFRQIURQWVWKHXVHUZLWKFRQIXVLQJVFUHHQVH[FHVVLYHGDWD
HQWU\ILHOGVRUXQFOHDUQDYLJDWLRQDOWRROVWKUHDWHQVWKHTXDOLW\RIWKHGDWDWKDWXVHUVHQWHU´   
307  See  supra  note  306;;  Ken  Terry,  Voice  Recognition  Moves  Up  a  Notch:  When  the  Computer  
Can  Type  While  You  Talk,  You  Save  Money  and  Time,  81  MED.  ECON.  TCP11  (2004).    
308  See  supra  note  216  and  accompanying  text.  
309  Krystl  Haerian  et  al.,  Use  of  Clinical  Alerting  to  Improve  the  Collection  of  Clinical  Research  
Data,  2009  AMIA  ANN.  SYMP.  PROC.  218,  219-­20.  
310  Id.  at  219.    
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larger   variance   from   those   previously   recorded.311   After   the   alerts   were  
implemented,  EHR  error  rates  were  reduced  from  2.4%  to  .9%.312  
As   healthcare   facilities   become   increasingly   interested   in   research   endeavors  
that  utilize  electronic  databases,   they  may  demand  that  EHR  vendors  build  systems  
that   encourage   or   require   clinicians   to   capture   research-­relevant   data.   Similarly,  
healthcare  systems  may  train  their  employees  to  be  diligent  about  collecting  data  that  
is   needed   for   secondary   use.   Healthcare   providers   have   much   to   gain   from  
observational   research   using   biomedical   databases.   New   discoveries   can   lead   to  
better   patient   care,   cost   savings,   and   financial   profits   from   the   adoption   of   more  
effective  treatments.313  Those  who  wish  to  enjoy  these  benefits  should  be  motivated  
to  do   their  utmost   to  produce  data   that   is  accurate,   complete,   and  easily  usable   for  
research  purposes.  
B.  HUMAN  HANDS  
Technology   alone   cannot   remedy   the  weaknesses   of   biomedical   databases   and  
observational  study  outcomes.  Continuous  human  vigilance  and  human  intervention  
will  be  critical  to  the  integrity  of  the  research  endeavor.  Two  safeguards  of  particular  
importance   are   data   quality   assessment   and   careful   application   of   modern   causal  
inference  techniques.  
1.  Data  Quality  Assessment  
Analysts  will  need   to   take  steps   to  assess   the  validity  of  biomedical  data.   This  
could   be   accomplished   through   audits   that   scrutinize   a   sample   of   EHRs.314  
Researchers  would   select   a   randomly   chosen   sample   of   records,   review   them,   and  
then   interview   the  patients  at   issue   (and  possibly   their  caregivers)   to  determine   the  
UHFRUGV¶ DFFXUDF\ OHYHO7KLVSURFHVVZRXOG HQDEOH DQDO\VWV WR HVWLPDWH HUURU UDWHV
for   particular   databases   or   federated   systems   in   order   to   characterize   uncertainty  
about   research   results.315   If   data   analysts   are   receiving   information   from   multiple  
sources  and  do  not  have  access  to  patients,  their  ability  to  assess  data  quality  will  be  
more   limited.316   However,   they   may   be   able   to   compare   data   sets   from   different  
sources,   identify  anomalous  values,  and  ask  the  original  data  holders  to  verify  their  
accuracy.317  
                                                                                                  
311  Id.    
312  Id.  at  220.  
313  See  supra  Part  II.B.1.  
314  U.S.  GOV¶T  ACCOUNTABILITY  OFFICE,  GAO-­06-­54,  HOSPITAL  QUALITY  DATA:  CMS  NEEDS  
MORE  RIGOROUS  METHODS  TO  ENSURE  RELIABILITY  OF  PUBLICLY  RELEASED  DATA  5  (2006)  
GLVFXVVLQJWKH&HQWHUVIRU0HGLFDUHDQG0HGLFDLG6HUYLFHV¶SURFHVV³IRUHQVXULQJWKHDFFXUDF\RIWKH
TXDOLW\GDWDVXEPLWWHGE\KRVSLWDOVIRUWKH$38SURJUDP´/HRQ*)LQHHWDOHow  to  Evaluate  and  
Improve  the  Quality  and  Credibility  of  an  Outcomes  Database:  Validation  and  Feedback  Study  on  the  
UK  Cardiac  Surgery  Experience,  326  BRIT.  MED.  J.  25,  25-­26  (2003).  
315  See  Douglas  Curran-­Everett  &  Dale  J.  Benos,  Guidelines  for  Reporting  Statistics  in  Journals  
Published  by  the  American  Physiological  Society,  18  PHYSIOLOGY  GENOMICS  249,  250  (2004)  
(discussing  the  importance  of  reporting  uncertainty).  
316  Id.  
317  Michael  G.  Kahn  et  al.,  A  Pragmatic  Framework  for  Single-­Site  and  Multisite  Data  Quality  
Assessment  in  Electronic  Health  Record-­Based  Clinical  Research,  50  MED.  CARE  S21,  S22  (2012).  




Experts   have   also   developed   methods   to   validate   or   assess   the   quality   of  
annotation   in   genome   records.318   For   example,   a   guidance   document   for   genetic  
epLGHPLRORJLVWV SURSRVHV WKH FUHDWLRQ RI DQ LQGH[ WKDW DVVLJQV JUDGHV RI ³$´ %´
DQG³&´WRWKUHHLQGLFDWRUVDPRXQWRIHYLGHQFHH[WHQWRIUHSOLFDWLRQDQGSURWHFWLRQ
from   bias.319   The   index   would   also   generate   an   overall   assessment   of  
epidemiological  credibLOLW\DVEHLQJ³VWURQJ´³PRGHUDWH´RU³ZHDN´320  
,QYHVWLJDWRUVVKRXOGHPSOR\UHSXWDEOH³EHVWSUDFWLFH´JXLGHOLQHVIRUFRQGXFWLQJ
observational   research   using   biomedical   databases.   One   example   is   a   2011   FDA  
GUDIW JXLGDQFH GRFXPHQW HQWLWOHG ³%HVW 3UDFWLFHV Ior   Conducting   and   Reporting  
3KDUPDFRHSLGHPLRORJLF 6DIHW\ 6WXGLHV 8VLQJ (OHFWURQLF +HDOWKFDUH 'DWD 6HWV´321  
Likewise,   the   International   Journal   of   Epidemiology¶V Assessment   of   Cumulative  
Evidence   on   Genetic   Associations:   Interim   Guidelines   offers   guidance   to   genetic  
researchers.322  
Clinicians  and  researchers  could  also  employ  the  technique  of  crowdsourcing  to  
the  project  of  verifying  EHR  data.  &URZGVRXUFLQJRFFXUVZKHQDQHQWLW\HQDEOHV³D
SRSXODWLRQ FURZG WR VROYH D SUREOHP´323   XVLQJ DQ ³RSHQ FDOO´ WR LQGXFH an  
undefined,   large   network   of   people   rather   than   employees   to   perform   work. 324  
Patients  may   review   their   own  medical   records   and   often   have   access   to   some   of  
their   health   information   through   an   interactive   component   of   the   EHR   called   a  
personal  health  record.325  Patients  who  identify  EHR  errors  should  be  able  to  report  
them   easily   to   clinicians.   For   their   part,   clinicians   should   be   obligated   to   read   all  
error   alerts,   assess   them,   and   make   corrections   if   the   patient   has   in   fact   found   a  
mistake.326   Federal   regulations   already   allow   patients   to   review   their   records   and  
                                                                                                  
318  Klimke  et  al.,  supra  note  184,  at  168  (describing  methods  to  assess  annotation  quality,  
LQFOXGLQJFRPELQLQJGLIIHUHQWSLHFHVRIHYLGHQFH³LQRUGHUWRDVVLJQFRQILGHQFHOHYHOVWRDSDUWLFXODU
annotDWLRQ´  
319  John  P.  A.  Ioannidis  et  al.,  Assessment  of  Cumulative  Evidence  on  Genetic  Associations:  
Interim  Guidelines,  37  INT¶L  J.  EPIDEMIOLOGY  120,  122  (2008).  
320  Id.  at  126.  
321  FOOD  &  DRUG  ADMIN.,  BEST  PRACTICES  FOR  CONDUCTING  AND  REPORTING  
PHARMACOEPIDEMIOLOGIC  SAFETY  STUDIES  USING  ELECTRONIC  HEALTHCARE  DATA  SETS  (2013),  
available  at  http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/   
Guidances/UCM243537.pdf.  See  also  Simon  Sanderson  et  al.,  Tools  for  Assessing  Quality  and  
Susceptibility  to  Bias  in  Observational  Studies  in  Epidemiology:  A  Systematic  Review  and  Annotated  
Bibliography,  36  INT¶L  J.  EPIDEMIOLOGY  666,  666-­74  (2007)  (providing  guidance  concerning  
observational  studies  but  not  specifically  about  EHR-­based  research).  
322  See  Paolo  Boffetta  et  al.,  Recommendations  and  Proposed  Guidelines  for  Assessing  the  
Cumulative  Evidence  on  Joint  Effects  of  Genes  and  Environments  on  Cancer  Occurrence  in  Humans ,  
41  INT¶L  J.  EPIDEMIOLOGY  686,  686-­704  (2012);;  see  generally  Ioannidis  et  al.,  supra  note  319.  
323  Michael  Christopher  Gibbons,  Use  of  Health  Information  Technology  Among  Racial  and  
Ethnic  Underserved  Communities,  8  PERSP.  IN  HEALTH  INFO.  MGMT.  1,  6  (2011),  available  at  
http://perspectives.ahima.org/PDF/Winter_2011/Use_of_HIT_Among_Racial_and_Ethnic_Underserve
d_Communities/Use_of_HIT_Among_Racial_and_Ethnic_Underserved_Communities_final.pdf.   
324  Daren  C.  Brabham,  Crowdsourcing  as  a  Model  for  Problem  Solving:  An  Introduction  and  
Cases,  14  CONVERGENCE  75,  76  (2008);;  Jeff  Howe,  Crowdsourcing:  A  Definition,  CROWDSOURCING  
(June  2,  2006),  http://crowdsourcing.typepad.com/cs/2006/06/crowdsourcing_a.html.     
325  Paul  C.  Tang  et  al.,  Personal  Health  Records:  Definitions,  Benefits,  and  Strategies  for  
Overcoming  Barriers  to  Adoption,  13  J.  AM.  MED.  INFORMATICS  ASS¶N  121,  122  (2006)  (citing  
MARKLE  FOUND.,  CONNECTING  FOR  HEALTH:  THE  PERSONAL  HEALTH  WORKING  GROUP  FINAL  
REPORT  GHILQLQJDSHUVRQDOKHDOWKUHFRUGDV³DQHOHFWURQLFDSSOLFDWLRQWKURXJKZKLFK
individuals  can  access,  manage  and  share  their  health  information,  and  that  of  others  for  whom  they  
DUHDXWKRUL]HGLQDSULYDWHVHFXUHDQGFRQILGHQWLDOHQYLURQPHQW´   
326  In  some  cases,  patients  will  be  wrong  about  the  existence  of  an  error,  and  thus  clinicians  must  
scrutinize  error  reports  before  changing  EHR  entries.    
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request   amendment   in   case   of   error.327  Thus,   this   approach   is   novel   only   in   that   it  
would   affirmatively   encourage   patients   to   scrutinize   their   medical   files.   Patients  
should  submit  error  reports  through  WKHLU(+5V\VWHPV¶VHFXUHPHVVDJLQJIHDWXUH328  
or   a   dedicated   website   so   that   they   may   create   a   record   of   their   requests   and  
document  their  assertions  that  errors  exist.329    
2.  Causal  Inference  Techniques  
In   the   last   two   decades,   researchers   have   made   substantial   progress   in   the  
development   of   a   methodology   for   making   causal   inferences   from   observational  
data.  Causal  diagrams  (also  called  causal  graphs,  directed  acyclic  graphs,  or  DAGs)  
are  an  important  component  of  this  methodology  and  have  become  a  popular  tool  in  
the  fields  of  statistics,  biostatistics,  epidemiology,  and  computer  science.330  The  use  
of   sound   causal   inference   techniques   is   essential   for   analysis   of   large   amounts   of  
complex   data   from   biomedical   databases.   Lawyers   and   policy   officials   would   be  
well  advised  to  keep  abreast  of  causal  research  inference  developments  and  be  able  
to  understand  causal  diagrams.    
  
  
Figure  1:  Causal  diagram  showing  causal  arrows  between  treatment  variable  T,  
outcome  variable  O,  and  confounder  C.  
  
A  causal  diagram  consists  of  points  or  vertices,  each  representing  a  variable.331  
7KHUH LVDQDUURZRU³HGJH´A     B  connecting  a  variable  A   to  a  variable  B   if  A   is  
known   or   assumed   to   cause   B.332   The   variables   typically   include   a   treatment   or  
exposure  variable  (e.g.,  indicating  which  medication  a  patient  received),  an  outcome  
YDULDEOH HJ UHSUHVHQWLQJ D SDWLHQW¶V   disease   status),   and   a   number   of   covariates  
representing   clinical,   demographic,   and   possibly   genetic   factors.333   For   each   study  
                                                                                                  
327  See  +,3$$3ULYDF\5XOH&)5³$QLQGLYLGXDOKDVWKHULJKWWRKDYHD
covered  entity  amend  protected  health  information  or  a  record  about  the  individual  in  a  designated  
UHFRUGVHW´  
328  See  Hoffman  &  Podgurski,  supra  note  157,  at  1530,  1549  (describing  secure  messaging).  
329  See  Elizabeth  Pennisi,  3URSRVDOWRµ:LNLI\¶*HQ%DQN0HHWV6WLII5HVLVWDQFH,  319  SCI.  1598,  
1598  (2008)  (describing  a  controversy  regarding  the  process  for  correcting  errors  in  *HQ%DQN³WKH
86SXEOLFDUFKLYHRIVHTXHQFHGDWD´  
330  JUDEA  PEARL,  CAUSALITY  65-­68  (2d  ed.  2009);;  Tyler  J.  VanderWeele  &  Nancy  C.  Staudt,  
Causal  Diagrams  for  Empirical  Legal  Research:  Methodology  for  Identifying  Causation,  Avoiding  
Bias,  and  Interpreting  Results,  10  L.  PROBABILITY  &  RISK  329,  329-­30  (2011).    
331  VanderWeele  &  Staudt,  supra  note  330,  at  333;;  Jeffrey  Swanson  &  Jennifer  Ibrahim,  
Picturing  Public  Health  Law  Research:  Using  Causal  Diagrams  to  Model  and  Test  Theory ,  PUB.  
HEALTH  L.  RES.  1,  6  (2011),  http://publichealthlawresearch.org/sites/default/files/SwansonIbrahim-­
CausalDiagrams-­March2012.pdf.  
332  See  supra  note  307.  
333  Swanson  &  Ibrahim,  supra  note  331,  at  6.  




VXEMHFW UHVHDUFKHUV REWDLQ YDOXHV IRU DOO YDULDEOHV LI SRVVLEOH IURP WKH VXEMHFW¶V
medical   record   or   other   sources.334   A   very   simple   causal   diagram,   reflecting   the  
relationships   between   a   treatment   variable   T,   and   outcome   variable   O,   and   a  
confounder  C,   is   shown   in   Figure   1.   The   FDXVDO GLDJUDP UHSUHVHQWV LQYHVWLJDWRUV¶
assumptions   about   causal   relationships   between   variables   in   a   particular   study   or  
about  the  absence  of  such  relationships.335  ,W LV LQWHQGHGWREH³DPDSRI   FDXVH
DQG HIIHFW UHODWLRQV´ DOORZLQJ UHVHDUFKHUV WR XQGHUVWDQG UHODWLRQVKLSV DPRQJ
relevant   variables   so   that   they   can   construct   valid   statistical   models,   avoid  
confounding,  and  correctly  interpret  study  results.336  In  the  process  of  creating  causal  
diagrams,   analysts   attempt   to   specify   the   causal   relationships   and   dependencies  
among   all   relevant   factors   involved   in   a   particular   problem,   leaving   the   ultimate  
question  of  the  relationship  between  the  exposure  of  interest  and  the  outcome  to  be  
discovered  through  research.337    
Causal  diagrams  can  thus  assist  analysts  in  determining  the  measures  to  be  used  
in   a   study   and   in   understanding   potential   sources   of   bias.338   They   provide   a   clear,  
visual  means  to  depict  assumptions  about  the  relationships  of  variables  and  highlight  
complexities   that   researchers   might   overlook   in   the   absence   of   the   graphs.339  
Moreover,   researchers  have  derived  precise  conditions,   in   terms  of  a  correct  causal  
GLDJUDP IRU VHOHFWLQJ D VHW RI FRQIRXQGHUV WR DGMXVW IRU LQ RUGHU WR ³LGHQWLI\´
(statistically   characterize)   a   given   causal   effect.340   -XGHD 3HDUO¶V ³%DFN-­Door  
&ULWHULRQ´FRQVWLWXWHVDZHOO-­known  example.341  It  characterizes  the  circumstances  in  
which   a   set   of   variables   is   sufficient,   if   adjusted   for,   to   eliminate   confounding   by  
³EORFNLQJ´LQDWHFKQLFDOVHQVHDOO³EDFN-­GRRU´SDWKVLQDFDXVDOGLDJUDPEHWZHHQ
the  treatment/exposure  variable  and  the  outcome  variable.342  Note  that  an  unblocked  
(open)   back-­door   path   permits   a   confounder   to   induce   a   spurious   association  
between  the  treatment/exposure  and  the  outcome.343  Such  conditions  can  be  checked  
algorithmically,  given  a  correctly  specified  causal  diagram  for  a  study.344   In  Figure  
1,   the  open  back-­door  path  T     C     O   represents   the  ability  of   the  variable  C   to  
confound   estimation   of   the   causal   effect   of   the   treatment   variable   T   upon   the  
outcome   variable   O.345   This   back-­door   path   can   be   blocked   by   conditioning   on  
(adjusting  for)  the  confounder  C,  e.g.,  by  restricting  the  analysis  to  a  single  level  of  
C.346    
Returning   to   our   previous   example,   suppose   T   indicates   the   drug   a   patient   is  
given  to  treat  high  blood  pressure  (1:  diuretic,  2:  beta  blocker);;  C  is  an  indicator  for  
evidence  of  clinical  cardiovascular  disease  (1:  yes,  0:  no);;  and  the  outcome  variable  
                                                                                                  
334  Id.  
335  VanderWeele  &  Staudt,  supra  note  330,  at  332.  
336  Id.  at  329.    
337  Brookhart  et  al.,  supra  note  190,  at  S116.  
338  Id.;;  Swanson  &  Ibrahim,  supra  note  331,  at  1.    
339  VanderWeele  &  Staudt,  supra  note  330,  at  335.  
340  PEARL,  supra  note  330,  at  65-­68;;  Ilya  Shpitser  et  al.,  On  the  Validity  of  Covariate  Adjustment  
for  Estimating  Causal  Effects,  26TH  ANN.  CONF.  ON  UNCERTAINTY  IN  ARTIFICIAL  INTELL.  (UAI-­10)  
527,  527-­26  (2010);;  Tyler  J.  VanderWeele  &  Ilya  Shpitser,  A  New  Criterion  for  Confounder  Selection ,  
67  BIOMETRICS  1406,  1406  (2011).  
341  PEARL,  supra  note  330,  at  79-­H[SODLQLQJWKH³EDFN-­door  FULWHULRQ´  
342  Id.  
343  VanderWeele  &  Staudt,  supra  note  330,  at  335.  
344  PEARL,  supra  note  330,  at  72-­76  (discussing  how  the  effect  of  interventions  is  computed).   
345  Id.  
346  Id.  
534   AMERICAN  JOURNAL  OF  LAW  &  MEDICINE   VOL.  39  NO.  4  2013  
O   indicates  whether   the  patient  had  a  heart  attack  after   treatment   (1:  yes,  0:  no). 347  
Restricting   the   study   to   patients   with   C   =   0,   for   whom   there   is   no   evidence   of  
clinical   cardiovascular   disease,   prevents   distortion   of   the   causal   effect   of   T  
(treatment)  on  O   (outcome)  by  a  spurious,  noncausal  association  between  T  and  O.  
Such  an  association  could  occur  because  use  of  beta  blockers,  rather  than  diuretics,  
is   an   indicator   of   more   severe   disease   and   greater   pre-­treatment   risk   of   heart  
attack.348  Without  such  an  adjustment,  beta  blockers  could  appear  less  effective  than  
they   really   are   because  more   of   the   patients   taking   them  would   likely   suffer   heart  
attacks  caused  by  their  existing  cardiovascular  disease.  
Confounding,   selection   bias,   and   measurement   error   may   also   affect  
observational  studies  of  possible  causal  relationships  between  genes  and  diseases. 349  
To   address   these   challenges,   researchers   have   advocated   for   the   use   of   causal  
inference   methodology,   including   causal   diagrams,   in   genetic   studies.350   For  
example,  systems  biologists  employ  graphical  models  to  depict  what  is  known  about  
the  molecular  networks  by  which  genes  regulate  (or  misregulate)  the  functioning  of  
other  genes.351  The  successful  use  of  causal  inference  techniques  in  medical  genetics  
is  synergistically  related   to  efforts   to  elucidate   the  complex  biological  networks  by  
which  genes  influence  disease.352  
If   properly   used,   causal   diagrams,   and   modern   causal   inference   methodology  
more  generally,  can  promote  more  accurate  research  results,  which  can  lead  to  sound  
public  health  policies  and  regulations.  Experts  have  also  noted  that  causal  graphs  can  
be  used  to  portray  the  relationship  between  the  law  and  human  behavior  in  order  to  
ascertain  that  legal  interventions  are  having  the  desired  effect.353  
                                                                                                  
347  See  supra  notes  252-­254  and  accompanying  text.  
348  Id.  
349  John  Attia  et  al.,  How  to  Use  an  Article  About  Genetic  Association  B:  Are  the  Results  of  the  
Study  Valid?  301  J.  AM.  MED.  ASS¶N  191,  191  (2009);;  Sara  Geneletti  et  al.,  Assessing  Causal  
Relationships  in  Genomics:  From  Bradford-­Hill  Criteria  to  Complex  Gene-­Environment  Interactions  
and  Directed  Acyclic  Graphs,  8  EMERGING  THEMES  IN  EPIDEMIOLOGY  1,  5  (2011).  For  example,  
researchers  have  found  that  standard  statistical  approaches  for  estimating/testing  direct  genetic  effects  
may  yield  biased  estimates  when  there  is  a  non-­genetic  link  between  the  target  phenotype  and  another  
phenotype.  Stijn  Vansteelandt  et  al.,  On  the  Adjustment  for  Covariates  in  Genetic  Association  
Analysis:  A  Novel,  Simple  Principle  to  Infer  Direct  Causal  Effects ,  33  GENETIC  EPIDEMIOLOGY  394,  
395  (2009).  
350  Nuala  A.  Sheehan  et  al.,  Mendelian  Randomisation:  A  Tool  for  Assessing  Causality  in  
Observational  Epidemiology,  in  GENETIC  EPIDEMIOLOGY  153,  153-­66  (M.  Dawn  Teare  ed.,  2011);;  
Alexander  V.  Alekseyenko  et  al.,  Causal  Graph-­Based  Analysis  of  Genome-­Wide  Association  Data  in  
Rheumatoid  Arthritis,  6  BIOLOGY  DIRECT  25,  26  (2011);;  Steven  S.  Coughlin,  Quantitative  Models  for  
Causal  Analysis  in  the  Era  of  Genome  Wide  Association  Studies ,  4  OPEN  HEALTH  SERV.  POL¶Y  J.  118,  
120  (2011).  For  example,  Geneletti  et  al.  present  a  framework  of  assessing  causal  relationships  in  
FOLQLFDOJHQRPLFVWKDWLQWHJUDWHV$XVWLQ%UDGIRUG+LOO¶VLQIOXHQWLDOJXLGHOLQHVIRUDVVHVVLQJFDXVDOLW\
on  one  hand,  with  the  use  of  graphical  models  (depicting  both  causal  and  non-­causal  associations),  on  
the  other  hand.  See  Geneletti  et  al.,  supra  note  349,  at  5-­6.  
351  Celine  Lefebvre  et  al.,  Reverse-­Engineering  Human  Regulatory  Networks,  4  WILEY  
INTERDISCIP.  REV.  SYST.  BIOLOGY  MED.  311,  311  (2012).  Such  regulation  occurs  indirectly,  via  the  
products  of  gene  expression,  namely  RNA  and  proteins.  Id.  at  312.  
352  Albert-­László  Barabasi  et  al.,  Network  Medicine:  A  Network-­Based  Approach  to  Human  
Disease,  12  NATURE  REV.  GENETICS  56,  56  (2011).  
353  Swanson  &  Ibrahim,  supra  note  331,  at  1;;  Evan  Anderson  et  al.,  Measuring  Statutory  Law  and  
Regulations  for  Empirical  Research,  PUB.  HEALTH  L.  RES.  PROGRAM  1,  12  (2012),  
http://publichealthlawresearch.org/sites/default/files/MeasuringLawRegulationsforEmpiricalResearch -­
Monograph-­AndersonTremper-­0DUFKSGIVWDWLQJWKDW³>E@\forcing  researchers  to  identify  
plausible  links  between  the  law  and  health  outcomes,  causal  diagrams  help  flush  out  the  legal  inputs  
UHOHYDQWWRWKHTXHVWLRQRILQWHUHVW´  




Nevertheless,   causal   diagrams   support   valid   causal   inferences   only   if   they  
include  all  relevant  variables  and  reflect  the  true  causal  relationships  among  them. 354  
Analysts  must  make  subjective  decisions  in  selecting  which  variables  and  arrows  to  
include,   and   their   own   erroneous   assumptions,   biases,   or   carelessness   can  
contaminate   the   final   product.355   Thus,   the   causal   diagram   in   Figure   1   would   be  
incorrect   if   there  were   in   truth  another  variable   S  and  a  path  T     S     O   (called  a  
³FROOLGHU´WKDWZDVXQNQRZQWRWKHUHVHDUFKHUV$VGLVFXVVHGLQDSULRUH[DPSOHWKH
values  of  this  variable  could  indicate  whether  individual  patients  are  lost   to  follow-­
up  and  cannot  be  included  in  the  study.  Losing  such  patients  could  lead  to  selection  
bias   that   exaggerates   or   diminishes   the   apparent   effectiveness   of   one   of   the  
treatments  under  study.356    
The   use   of   genomic   data  with  many   thousands   of   variables,   though   desirable,  
also   complicates   causal   inference.   As   genetic   discoveries   emerge,   researchers  
routinely   need   to   determine   whether   to   include   genetic   variables   as   factors   that  
influence   disease   vulnerability   or   treatment   success.357   Geneticists   have   identified  
over  6000  single-­gene  disorders358  and  believe  that  essentially  every  human  disease  
has   a   genetic   component.359   Even   vulnerability   to   infection   can   be   affected   by  
individual   genotype,  which   can   render   some  people   resistant   to   infectious  diseases  
including  AIDS.360  
In   the   future,   expert   panels   may   be   able   to   develop   widely   accepted   causal  
diagrams   for   disease-­related   causal   influences   about   which   there   is   general  
agreement.   Individual   researchers   would   be   free   to   customize   them   by   adding   or  
removing   links   to   reflect   their   own   causal   hypotheses,   but   such   diagrams   could  
provide  significant  guidance  to  analysts.  
Public  health  officials  and  legal  practitioners  with  expertise  in  causal  inference  
methodology  will  be  better  equipped  to  understand  study  outcomes,  ask  appropriate  
                                                                                                  
354  In  addition,  statistical  analysis  of  causal  effects  based  on  a  causal  diagram  is  valid  only  if  
certain  strong  assumptions  hold  that  relate  the  diagram  to  the  underlying  probability  distribution  of  
the  variables.  A.  Philip  Dawid,  Beware  of  the  DAG!,  6  J.  MACHINE  LEARNING  RES.  59,  68  (2008),  
available  at  http://jmlr.csail.mit.edu/proceedings/papers/v6/dawid10a/dawid10a.pdf.  
355  See  Brookhart  et  al.,  supra  QRWHDW6H[SODLQLQJWKDW³LQPDQ\VWXGLHVRIPHGLFDO
interventions,  the  available  subject-­matter  knowledge  is  inadequate  to  specify  with  any  degree  of  
certainty  the  causal  connecWLRQVEHWZHHQYDULDEOHV´  
356  See  supra  notes  231,  233-­DQGDFFRPSDQ\LQJWH[W$VVXPHWKH³FROOLGHU´YDULDEOHS  
indicates  whether  a  study  subject  is  lost  to  follow-­up  (1:  yes,  0:  no)  and  is  influenced  by  the  disease  
outcome  O  (1:  cured,  0:  not  cured)  under  investigation  and  by  treatment  T  (1:  drug  A,  0:  drug  B).  If  S  
ZDVDOZD\V]HURLQGLFDWLQJ³QRWORVWWRIROORZXS´IRUVWXG\SDUWLFLSDQWVWKHQWKHSDWKT     S     O  
would  be  open  and  possibly  create  a  spurious  association  between  T  and  O  resulting  in  selection  bias.  
For  example,  suppose  that  a  number  of  study  subjects  stopped  going  to  the  doctor  because  of  
unpleasant  side  effects  of  drug  A  (assume  drug  B  has  no  side  effects)  or  because  they  experienced  no  
improvement  in  their  disease  symptoms  and  became  discouraged.  Among  subjects  who  received  drug  
A,  those  who  completed  the  treatment  regime  might  have  experienced  an  atypically  strong  therapeutic  
effect  from  A,  since  they  were  willing  to  tolerate  its  side  effects.  Consequently,  treatment  A  might  
appear  more  effective  overall,  when  compared  to  treatment  B,  than  it  really  is.  
357  Genetic  Disease  Information  ±  Pronto!,  HUMAN  GENOME  PROJECT  INFO.,  
http://web.archive.org/web/20130430183952/http://www.ornl.gov/sci/techresources/Human_Genome/
medicine/assist.shtml  (last  modified  Mar.  07,  2012)  (accessed  by  searching  for  Human  Genome  
Project  Information  in  the  Internet  Archive);;  Understanding  Human  Genetic  Variation,  NAT¶L  INSTS.  
OF  HEALTH  OFFICE  OF  SCI.  EDUC.,  
http://science.education.nih.gov/supplements/nih1/genetic/guide/genetic_variation1.htm  (last  visited  
Oct.  15,  2013).  
358  Genetic  Disease  Information  ±  Pronto!,  supra  note  357  (indicating  that  many  other  diseases  
are  multi-­factorial,  chromosomal,  and  mitochondrial).  
359  Understanding  Human  Genetic  Variation ,  supra  note  357.  
360  Id.  
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questions,  and  differentiate  between  good  and  bad  science.  They   thus  will  be   more  
likely  to  respond  to  emerging  discoveries  appropriately.  
Causal  diagrams  might  even  be  useful  as  litigation  tools.  In  complex  tort  cases  
involving   questions   of   causation,   lawyers   could   ask   experts   to   develop   plausible  
causal   diagrams   that   depict   the   pDUWLHV¶ XQGHUVWDQGLQJ RI KRZ SODLQWLIIV¶ LQMXULHV
occurred.  Experts  on  opposing  sides  are  unlikely  to  agree  about  the  details  of  causal  
GLDJUDPV DQG FRXOG XVH FDXVDO LQIHUHQFH PHWKRGRORJ\ WR DWWDFN WKHLU RSSRQHQWV¶
assumptions   and   assertions.   Fact-­finders   would   then   determine   which   diagram   is  
most  accurate  before  deciding  which  party  will  prevail.  
C.  EDUCATION  AND  PREVENTION  OF  RESEARCH  MISUSE    
Biomedical  databases  and  federated  systems  will  provide  an  abundance  of  new  
data361   that   can   be   harnessed   to   bring   great   benefits   to   society   but   could   also   be  
abused.362   As   argued   above,   only   highly   skilled   researchers   who   understand   data  
quality   problems   and   causal   inference   methodology   are   likely   to   produce   reliable  
study   outcomes.363   The   public   and   even   policy   experts  may   be   too   credulous  with  
respect   to   information   that   is   drawn   from   large   databases   and   appears   to   be  
scientific.    
Numerous   studies   have   highlighted   how   difficult   it   is   for   many   people   to  
understand  statistical   information.364  One  study  surveyed  German  and  U.S.  citizens  
and  found  that  approximately  20%  of  citizens  could  not  determine  whether  1%,  5%,  
RUUHSUHVHQWHGWKH³ELJJHVWULVNRIJHWWLQJDGLVHDVH´365  Other  researchers  have  
JRQH DV IDU DV WR GHFODUH WKDW PRGHUQ VRFLHWLHV VXIIHU IURP ³FROOHFWLYH VWDWLVWLcal  
LOOLWHUDF\´366    
  Consequently,   the  development  of   large-­scale  biomedical   databases   should  be  
accompanied  by  educational  programs  about  their  strengths  and  limitations. 367  Such  
programs   should   include   warnings   that   not   all   data   will   be   error-­free   and   not   all  
research   outcomes   can   be   trusted.   In   his   well-­known   book,   How   to   Lie   with  
Statistics'DUUHOO+XIIZULWHV WKDW WKH ODQJXDJHRI VWDWLVWLFV LV RIWHQ ³HPSOR\HG WR
VHQVDWLRQDOL]H LQIODWH FRQIXVH DQG RYHUVLPSOLI\´368   He   goes   on   to   assert   that  
³FURRNV DOUHDG\ NQRZ WKHVH WULFNV´ DQG WKHUHIRUH ³KRQHVWPHQPXVW OHDUQ WKHP LQ
self-­GHIHQVH´369    
                                                                                                  
361  See  supra  Parts  II.A,  II.B.1.  
362  See  supra  Part  V.  
363  See  supra  Parts  IV,  VI.A.1.  
364  See,  e.g.,  Timur  Kuran  &  Cass  R.  Sunstein,  Availability  Cascades  and  Risk  Regulation,  51  
STAN.  L.  REVGLVFXVVLQJ³WKHavailability  heuristic,  a  pervasive  mental  shortcut  
whereby  the  perceived  likelihood  of  any  given  event  is  tied  to  the  ease  with  which  its  occurrence  can  
EHEURXJKWWRPLQG´$PRV7YHUVN\	'DQLHO.DKQHPDQAvailability:  A  Heuristic  for  Judging  
Frequency  and  Probability,  5  COGNITIVE  PSYCHOLOGY  SURSRVLQJ³WKDWZKHQIDFHG
with  the  difficult  task  of  judging  probability  or  frequency,  people  employ  a  limited  number  of  
KHXULVWLFVZKLFKUHGXFHWKHVHMXGJPHQWVWRVLPSOHURQHV´   
365  Mirta  Galesic  &  Rocio  Garcia-­Retamero,  Statistical  Numeracy  for  Health:  A  Cross-­Cultural  
Comparison  with  Probabilistic  National  Samples ,  170  ARCHIVES  INTERNAL  MED.  462,  467  (2010).  In  
DGGLWLRQ³DOPRVWFRXOGQRWDQVZHUZKHWKHULQLQRULQUHSUHVHQWVWKHODUJHVW
ULVN´DQGQHDUO\³FRXOGQRWVWDWHZKDWSHUFHQWDJHRILV´Id.  
366  Gerd  Gigerenzer  et  al.,  Helping  Doctors  and  Patients  Make  Sense  of  Health  Statistics ,  8  
PSYCHOLOGY  SCI.  PUB.  INT.  53,  54  (2007).  
367  See  Hoffman  &  Podgurski,  supra  note  8,  at  140-­41  (developing  a  more  detailed  proposal  for  
educational  programs  regarding  EHR  databases).  
368  DARRELL  HUFF,  HOW  TO  LIE  WITH  STATISTICS  8  (1954).    
369  Id.  at  9.  




To   this   end,   the   National   Institutes   of   Health   could   construct   a   publicly  
available   website   about   sound   and   unsound   research   practices.   Other   educational  
messages   can   take   the   form   of   news   stories   disseminated   via   media   such   as  
television,  radio,  magazines,  and  news  websites.  
Lawyers,   judges,   and   legislators   who   must   consider   biomedical   data   should  
receive   training   focusing  on   observational   research   and   its   legal   implications.  Law  
schools   should   offer   courses   on   modern   causal   inference   methodology,   which   is  
becoming  essential  for  understanding  and  assessing  scientific  evidence.  In  addition,  
continuing  education  courses  on  data  analysis  should  be  available  to  legal  and  policy  
professionals.  Without   such   preparation,   they   will   be   ill-­equipped   to   engage   with  
expert  witnesses  or  policy  advocates  on  the  subject.  
Peer-­review  journal  editors  will  also  need  to  be  familiar  with  the  complexities  of  
biomedical  database  research.  Reviewers  for  articles  about  observational  studies  that  
rely   on   electronic   databases   should   have   expertise   not   only   with   respect   to   the  
underlying   subject  matter,   but   also   concerning   the   research  methodology.   In  2008,  
The  Journal  of  Clinical  Epidemiology  published  The  Strengthening  the  Reporting  of  
Observational   Studies   in   Epidemiology   (STROBE)   Statement,   which   included   a  
detailed   checklist   of   items   that   researchers   should   discuss   in   their   reports,   such   as  
study   design,   bias,   and   generalizability.370   Many   top   journals   instruct   authors   to  
comply   with   the   STROBE   statement   and   presumably   scrutinize   submitted  
manuscripts   to   ascertain   that   the   required   items   are   covered.371   In   the   future,   the  
checklist   may   need   to   be   expanded   to   account   for   matters   that   are   specific   to  
biomedical  databases.  
It  will  be  far  more  difficult  to  achieve  any  quality  control  for  the  work  product  
of   amateur   investigators   who   access   publicly   available   databases.   As   a   first   step,  
however,   access  may   be   conditioned  on   individuals   taking   a   short   (e.g.,   one   hour)  
online  course  about  observational   research   followed  by  a   simple  quiz  at   the  end   to  
test   learning.  This  obligation  may  deter   individuals  who  are  not  serious  about   their  
research  project  and  do  not  want  to  spend  the  time  taking  the  session.  Others  may  be  
convinced   that   research   is  a  serious  and  demanding  endeavor  and  decide   to  partner  
with  experienced  researchers  or  abandon  frivolous  research  pursuits.     
VII.  CONCLUSION  
The   advent   of   large-­scale   biomedical   databases   brings   with   it   the   prospect   of  
significant  advances  in  the  medical  and  social  policy  arenas  coupled  with  the  risks  of  
confusion,   uncertainty,   or   even   deception.   In   the   foreseeable   future,   computerized  
observational   studies   may   well   be   a   familiar   tool   for   regulators,   public   health  
officials,  and  litigators.  But  members  of  the  legal  community  who  will  rely  on  these  
studies  to  formulate  public  policy  or  to  support  litigation  claims  must  understand  the  
challenges   of   conducting   valid   database   research   and   learn   to   distinguish   good  
                                                                                                  
370  Erik  von  Elm  et  al.,  The  Strengthening  the  Reporting  of  Observational  Studies  in  
Epidemiology  (STROBE)  Statement:  Guidelines  for  Reporting  Observational  Studies ,  61  J.  CLINICAL  
EPIDEMIOLOGY  344,  346-­47  (2008).  
371  See  Instructions  for  Authors,  BMJ  OPEN,  http://bmjopen.bmj.com/site/about/guidelines.xhtml  
(last  visited  Oct.  15,  2013);;  JAMA  Instructions  for  Authors,  JAMA  NETWORK,  
http://jama.jamanetwork.com/public/instructionsForAuthors.aspx  (last  updated  Sept.  10,  2013);;  Types  
of  Article  and  Manuscript  Requirements,  LANCET,  http://www.thelancet.com/lancet-­neurology-­
information-­for-­authors/article-­types-­manuscript-­requirements  (last  visited  Oct.  15,  2013).    
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VFLHQFH IURP EDG 7KLV SRLQW LVPDGH FOHDU LQ -RKQ ,RDQQLGLV¶ SURYRFDWLYHO\ WLWOHG
HVVD\³:K\0RVW3XEOLVKHG5HVHDUFK)LQGLQJV$UH)DOVH´372  
Awareness   of   the   potential   for   selection   bias,   measurement   bias,   and  
confounding  bias,  and  of  how  these  biases  can  be  reduced  or  eliminated  is  critical  to  
appropriate   assessment   of   research   outcomes.   Similarly,   analysts   must   understand  
the  threats  to  study  validity  that  are  posed  by  data  entry  and  processing  errors,  EHR  
gaps   or   fragmentation,   and   data   standardization   problems.   These   pitfalls   are  
recognized  by  experts  in  epidemiology,  pharmacoepidemiology,  bioinformatics,  and  
other   fields   who   generally   produce   highly   skilled   and   statistically   sophisticated  
work.   However,   non-­scientists   must   also   recognize   these   challenges.   When  
communicating   study   results,   researchers  must   frankly   explain   all   such   threats   and  
what  was  done  to  address  them  and  must  characterize  as  objectively  as  possible  all  
elements  of  uncertainty  about  the  results.  
0DUN7ZDLQSRSXODUL]HGWKHVD\LQJ³[t]here  are  three  kinds  of  lies:  lies,  damned  
OLHVDQGVWDWLVWLFV´373  A  danger  exists  that  if  the  public  is  repeatedly  duped  by  false  
or  misleading   research  outcomes,   it  will   come   to   scorn   the   entire  medical   research  
endeavor.   It   is   only   with   appropriate   insight   and   sophisticated   approaches   to  
conducting   and   interpreting   observational   studies   that   biomedical   databases   can  
fulfill  their  hoped-­for  promise  and  promote  much  societal  good.    
                                                                                                  
372  Ioannidis,  supra  note  77,  at  696.  
373  Mark  Twain,  Chapters  from  my  Autobiography²XX,  186  N.  AM.  REV.  465,  471  (1907),  
reprinted  in  MARK  TWAIN,  CHAPTERS  FROM  MY  AUTOBIOGRAPHY  ch.  20,  at  471  (Shelley  Fisher  
Fishkin  ed.,  Oxford  Univ.  Press  1996).  
